<SEC-DOCUMENT>0001213900-17-007992.txt : 20170728
<SEC-HEADER>0001213900-17-007992.hdr.sgml : 20170728
<ACCEPTANCE-DATETIME>20170728091705
ACCESSION NUMBER:		0001213900-17-007992
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		9
CONFORMED PERIOD OF REPORT:	20170727
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170728
DATE AS OF CHANGE:		20170728

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36374
		FILM NUMBER:		17988027

	BUSINESS ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		646-677-3875

	MAIL ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k072817_actiniumpharma.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; padding: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0; padding: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CURRENT
REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pursuant
to Section 13 or 15(d) of the</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities
Exchange Act of 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Report (Date of earliest event reported): July 27, 2017</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ACTINIUM
PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>000-52446</B></FONT></TD>
    <TD STYLE="width: 2%; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>74-2963609</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
        or other jurisdiction<BR>
</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of&nbsp;incorporation)</FONT></P></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission
    File Number)</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS
        Employer</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
        No.)</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: bottom; width: 49%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>275
        Madison Avenue, 7th Floor</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>New
        York, NY</B></FONT></P></TD>
    <TD STYLE="vertical-align: top; width: 2%; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 49%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10016</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&rsquo;s
telephone number, including area code: <B>(646) 677-3870</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 100%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>N/A</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former
    name or former address, if changed since last report)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (<U>see</U> General Instruction A.2. below):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: left; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="width: 94%; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&#9744;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&#9744;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&#9744;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item&nbsp;1.01.
Entry into a Material Definitive Agreement.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify">On July 28, 2017, Actinium Pharmaceuticals,
Inc. (the &ldquo;Company&rdquo;) entered into an underwriting agreement (the &ldquo;Underwriting Agreement&rdquo;) with Oppenheimer
&amp; Co. Inc., as representative of the several underwriters party thereto (the &ldquo;Underwriters&rdquo;), relating to the
issuance and sale (the &ldquo;Offering&rdquo;) of 21,500,000 shares (the &ldquo;Shares&rdquo;) of the Company&rsquo;s common stock,
$0.001 par value per share (the &ldquo;Common Stock&rdquo;), and warrants to purchase 18,275,000 shares of Common Stock (the &ldquo;Warrants&rdquo;).
Each share of Common Stock is being sold together with a warrant to purchase .85 of a share of Common Stock, at a price to the
public of $0.75 per share and related warrant (the &ldquo;Offering Price&rdquo;). Pursuant to the terms of the Underwriting Agreement,
the Underwriters have agreed to purchase the Shares and warrants from the Company at a price of $0.705 per share and related warrant.
The Warrants will be exercisable commencing on the issuance date at an exercise price equal to $1.05 per whole share of Common
Stock, subject to adjustments as provided under the terms of the Warrants. The Warrants are exercisable for five years from the
date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The net proceeds to the Company from the
sale of the Shares and warrants, after deducting the underwriting discounts and other estimated offering expenses payable by the
Company, are expected to be approximately $15 million The Offering is expected to close on August 2, 2017, subject to the satisfaction
of customary closing conditions.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Offering is being made pursuant to the Company&rsquo;s effective shelf registration statement on Form S-3 (File No.&nbsp;333-194768)
filed with the Securities and Exchange Commission on March&nbsp;24, 2014, and declared effective on April&nbsp;17, 2014, including
the base prospectus dated April 17, 2014 included therein and the related preliminary prospectus supplement and prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing,
indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as
amended, other obligations of the parties, and termination provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Underwriting Agreement, subject to certain exceptions, the Company and its directors and officers have agreed not to sell
or otherwise dispose of any of the Company&rsquo;s securities held by them for a period ending 90 days after the date of the final
prospectus supplement relating to the Offering without first obtaining the written consent of the Representative.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing is only a brief description of the material terms of the Underwriting Agreement, does not purport to be a complete description
of the rights and obligations of the parties thereunder, and is qualified in its entirety by reference to the Underwriting Agreement
that is filed as Exhibit 1.1 to this Current Report on Form 8-K and incorporated by reference herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Underwriting Agreement has been attached hereto as an exhibit to provide investors and security holders with information regarding
its terms. It is not intended to provide any other factual information about the Company. The representations, warranties and
covenants contained in the Underwriting Agreement were made only for purposes of the Underwriting Agreement and as of specific
dates, were solely for the benefit of the parties to the Underwriting Agreement, and may be subject to limitations agreed upon
by the contracting parties, including being qualified by confidential disclosures exchanged between the parties in connection
with the execution of the Underwriting Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
legal opinion of The Matt Law Firm, PLLC relating to the Common Stock and Warrants being offered is filed as Exhibit 5.1 to this
Current Report on Form&nbsp;8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
7.01. Regulation FD Disclosure.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 27, 2017, the Company issued a press release announcing that it intended to make a public offering of shares of the Common
Stock and Warrants. On July 28, 2017, the Company issued a press release announcing the pricing and terms of the Offering. Copies
of the two press releases are attached hereto as Exhibits 99.1 and 99.2, respectively, and are each incorporated herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the rules and regulations of the Securities and Exchange Commission, the information in this Item 7.01 disclosure, including
Exhibits 99.1 and 99.2 and information set forth therein, is deemed to have been furnished and shall not be deemed to be &ldquo;filed&rdquo;
under the Securities Exchange Act of 1934.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item&nbsp;9.01</B>&nbsp;<B>Financial
Statements and Exhibits.</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Exhibits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the rules and regulations of the Securities and Exchange Commission, the attached exhibits are deemed to have been filed with
the Securities and Exchange Commission:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify; text-indent: 48.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; width: 9%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    Number</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 90%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="f8k072817ex1i_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting Agreement, dated as of July 28, 2017,&nbsp;by and between Actinium Pharmaceuticals, Inc. and Oppenheimer &amp; Co. Inc.. as representative of the several underwriters party thereto.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="f8k072817ex5i_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of The Matt Law Firm, PLLC.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="f8k072817ex10i_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="f8k072817ex5i_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of The Matt Law Firm, PLLC (included in Exhibit 5.1).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="f8k072817ex99i_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release issued by Actinium Pharmaceuticals, Inc. dated July 27, 2017.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="f8k072817ex99ii_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release issued by Actinium Pharmaceuticals, Inc. dated July 28, 2017.</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:&nbsp;July
    28, 2017</FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ACTINIUM
    PHARMACEUTICALS, INC.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; width: 60%; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 36%; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Sandesh Seth&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;Sandesh
        Seth</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;&nbsp;&nbsp;Chairman of the Board &amp; CEO</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; margin-top: 0; text-align: center; margin-bottom: 0">-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4-</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>



<P STYLE="margin: 0; padding: 0; font: 10pt Times New Roman, Times, Serif"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>f8k072817ex1i_actinium.htm
<DESCRIPTION>UNDERWRITING AGREEMENT, DATED AS OF JULY 28, 2017, BY AND BETWEEN ACTINIUM PHARMACEUTICALS, INC. AND OPPENHEIMER & CO. INC.. AS REPRESENTATIVE OF THE SEVERAL UNDERWRITERS PARTY THERETO
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: right; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exhibit
1.1</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Actinium
Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>21,500,000</B> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares
of Common Stock </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>and</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants
to Purchase up to 18,275,000 Shares of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDERWRITING
AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
28, 2017</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oppenheimer
&amp; Co. Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 -0.25in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
Representative of the</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 -0.25in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Several
Underwriters named</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 -0.25in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
Schedule I hereto</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">85
Broad Street</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York 10004</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actinium
Pharmaceuticals, Inc., a Delaware corporation (the &ldquo;Company&rdquo;) proposes, subject to the terms and conditions contained
herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the &ldquo;Underwriters&rdquo;), for
whom you are acting as Representative (the &ldquo;Representative&rdquo;), an aggregate of (i) 21,500,000 shares (the &ldquo;Shares&rdquo;)
of the Company&rsquo;s common stock, $0.001 par value per share (the &ldquo;Common Stock&rdquo;), and (ii) warrants (the &ldquo;Warrants&rdquo;)
to purchase up to an aggregate of 18,275,000 shares of Common Stock (the &ldquo;Warrant Shares&rdquo;). Each Share is being sold together
with .85 of a Warrant to purchase one Warrant Share. The Shares, the Warrants and the Warrant Shares are collectively referred
to as the &ldquo;Securities&rdquo;. The Shares and the Warrants will be issued separately, but will be purchased together in the
offering. The respective amounts of the Securities to be purchased by each of the several Underwriters are set forth opposite
their names on Schedule I hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has prepared and filed in conformity with the requirements of the Securities Act of 1933, as amended (the &ldquo;Securities
Act&rdquo;), and the published rules and regulations thereunder (the &ldquo;Rules&rdquo;) adopted by the Securities and Exchange
Commission (the &ldquo;Commission&rdquo;) a registration statement on Form&nbsp;S-3 (No. 333-194768), including a related prospectus
dated April 17, 2014 (the &ldquo;Base Prospectus&rdquo;) relating to common stock, preferred stock, debt securities, warrants,
rights, purchase contracts and units of the Company that may be sold from time to time by the Company in accordance with Rule&nbsp;415
of the Securities Act, and such amendments thereof as may have been required to the date of this Agreement. The Registration Statement
is effective and available for the offering and sale of the Shares as contemplated by this Agreement. Copies of such Registration
Statement (including all amendments thereof and all documents deemed incorporated by reference therein) and of the related Base
Prospectus have heretofore been delivered by the Company or are otherwise available to you.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term &ldquo;Registration Statement&rdquo; as used in this Agreement means the registration statement, including all exhibits,
financial schedules and all documents and information deemed to be part of the Registration Statement by incorporation by reference
or otherwise, as amended from time to time, including the information (if any) contained in the form of final prospectus filed
with the Commission pursuant to Rule 424(b) of the Rules and deemed to be part thereof at the time of effectiveness pursuant to
Rule 430B of the Rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company has filed an abbreviated registration statement to register additional Shares and Warrants pursuant to Rule 462(b)
under the Rules (the &ldquo;462(b) Registration Statement&rdquo;), then any reference herein to the Registration Statement shall
also be deemed to include such 462(b) Registration Statement. The term &ldquo;Preliminary Prospectus&rdquo; means the Base Prospectus,
together with any preliminary prospectus supplement used or filed with the Commission pursuant to Rule&nbsp;424 of the Rules,
in the form provided to the Underwriters by the Company for use in connection with the offering of the Securities. The term &ldquo;Prospectus&rdquo;
means the Base Prospectus, any Preliminary Prospectus and any amendments or further supplements to such prospectus, and including,
without limitation, the final prospectus supplement, filed pursuant to and within the limits described in Rule 424(b) with the
Commission in connection with the proposed sale of the Securities contemplated by this Agreement through the date of such Prospectus
Supplement. The term &ldquo;Effective Date&rdquo; shall mean each date that the Registration Statement and any post-effective
amendment or amendments thereto became or becomes effective, including as provided in Section 11(d) of the Securities Act. Unless
otherwise stated herein, any reference herein to the Registration Statement, any Preliminary Prospectus, the Statutory Prospectus
(as hereinafter defined) and the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein,
including pursuant to Item&nbsp;12 of Form S-3 under the Securities Act, which were filed under the Securities Exchange Act of
1934, as amended (the &ldquo;Exchange Act&rdquo;) on or before the date hereof or are so filed hereafter. Any reference herein
to the terms &ldquo;amend,&rdquo; &ldquo;amendment&rdquo; or &ldquo;supplement&rdquo; with respect to the Registration Statement,
any Preliminary Prospectus, the Statutory Prospectus or the Prospectus shall be deemed to refer to and include any such document
filed or to be filed under the Exchange Act after the date of the Registration Statement, any such Preliminary Prospectus, the
Statutory Prospectus or Prospectus, as the case may be, and deemed to be incorporated therein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company understands that the Underwriters propose to make a public offering of the Shares and the Warrants, as set forth in and
pursuant to the Statutory Prospectus (as hereinafter defined) and the Prospectus, as soon after the Effective Date and the date
of this Agreement as the Representative deems advisable. The Company hereby confirms that the Underwriters and dealers have been
authorized to distribute or cause to be distributed each Preliminary Prospectus, and are authorized to distribute the Prospectus
(as from time to time amended or supplemented if the Company furnishes amendments or supplements thereto to the Underwriters).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>Sale, Purchase, Delivery and Payment for the Shares and the Warrants</U>. On the basis of the representations, warranties and
agreements contained in, and subject to the terms and conditions of, this Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Company agrees to issue and sell to each of the Underwriters, and each of the Underwriters agrees, severally and not
jointly, to purchase from the Company, at a purchase price of $0.705 per Share and related Warrant, (i) the number of Shares
set forth opposite the name of such Underwriter under the column &ldquo;Number of Shares to be Purchased from the
Company&rdquo; on Schedule I to this Agreement and (ii) the number of Warrants set forth opposite the name of the Underwriter
under the column Number of Warrants to be Purchased from the Company&rdquo; on Schedule I to this Agreement, subject to
adjustment in accordance with Section 8 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Payment of the purchase price for, and delivery of certificates for, the Shares and the Warrants shall be made at the offices
of Oppenheimer &amp; Co. Inc., 85 Broad Street, 23<SUP>rd</SUP> Floor New York, New York 10004, at 10:00 a.m., New York City time,
on the third business day following the date of this Agreement or at such time on such other date, not later than ten (10) business
days after the date of this Agreement, as shall be agreed upon by the Company and the Representative (such time and date of delivery
and payment are called the &ldquo;Closing Date&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Payment shall be made to the Company by wire transfer of immediately available funds or by certified or official bank check or
checks payable in New York Clearing House (same day) funds drawn to the order of the Company, against delivery of certificates
representing the Shares and the Warrants to the account of the Representative for the respective accounts of the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Certificates evidencing the Shares and the Warrants shall be registered in such names and shall be in such denominations as the
Representative shall request at least two full business days before the Closing Date and shall be delivered by or on behalf of
the Company (i) in the case of the Shares, as directed by the Representative through the facilities of the Depository Trust Company
(&ldquo;DTC&rdquo;) for the respective accounts of the Underwriters and (ii) in the case of the Warrants, by physical delivery
to be received or directed by the Representative no later than one (1) business day following the Closing Date. The Company will
cause the certificates representing the Shares and the Warrants to be made available for checking and packaging, at such place
as is designated by the Representative, on the full business day before the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>Representations and Warranties of the Company</U>. The Company represents and warrants to each Underwriter as of the date hereof
and as of the Closing Date, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Company meets the requirements for use of Form S-3 under the Securities Act including the transaction requirements set forth
in General Instruction 1.B.1 of such form. The Company filed with the Commission the Registration Statement on such Form, including
a Base Prospectus, for registration under the Securities Act of the offering and sale of the Securities, and the Company has prepared
and used a Preliminary Prospectus in connection with the offer and sale of the Securities. When the Registration Statement or
any amendment thereof or supplement thereto was or is declared effective and as of the date of the most recent amendment to the
Registration Statement it (i) complied or will comply, in all material respects, with the requirements of the Securities Act and
the Rules and the Exchange Act and the rules and regulations of the Commission thereunder and (ii)&nbsp;did not or will not, contain
any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order
to make the statements therein not misleading. When any Preliminary Prospectus or Prospectus was first filed with the Commission
(whether filed as part of the Registration Statement or any amendment thereto or pursuant to Rule 424 of the Rules) and when any
amendment thereof or supplement thereto was first filed with the Commission, such Preliminary Prospectus or Prospectus as amended
or supplemented complied in all material respects with the applicable provisions of the Securities Act and the Rules and did not
or will not, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein
or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.
If applicable, each Preliminary Prospectus and the Prospectus delivered to the Underwriters for use in connection with this offering
was identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent
permitted by Regulation&nbsp;S-T. Notwithstanding the foregoing, none of the representations and warranties in this paragraph
2(a) shall apply to statements in, or omissions from, the Registration Statement, any Preliminary Prospectus or the Prospectus
made in reliance upon, and in conformity with, information herein or otherwise furnished in writing by the Representative on behalf
of the several Underwriters specifically for use in the Registration Statement, any Preliminary Prospectus or the Prospectus.
With respect to the preceding sentence, the Company acknowledges that the only information furnished in writing by the Representative
for use in the Registration Statement, any Preliminary Prospectus or the Prospectus is the statements contained in the 9th  paragraph
under the caption &ldquo;Underwriting&rdquo; in the Prospectus (collectively, the &ldquo;Underwriting Information&rdquo;).&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
As of the Applicable Time (as hereinafter defined), the Statutory Prospectus (as hereinafter defined) and the information set
forth on Schedule III hereto which will be provided orally to investors, all considered together (collectively, the &ldquo;General
Disclosure Package&rdquo;), did not include, nor will it include any untrue statement of a material fact or omit or will omit
to state any material fact required to be stated therein or necessary in order to make the statements therein, in the light of
the circumstances under which they were made, not misleading; provided, however, that this representation and warranty shall not
apply to statements in or omissions in the General Disclosure Package made in reliance upon and in conformity with the Underwriter
Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used in this Section and elsewhere in this Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Applicable
Time&rdquo; means 8:00&nbsp;am (Eastern time) on the date of this Underwriting Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Statutory
Prospectus&rdquo; as of any time means the Preliminary Prospectus relating to the Securities that is included in the Registration
Statement immediately prior to the Applicable Time, including any document incorporated by reference therein and any prospectus
supplement deemed to be a part thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The Registration Statement is effective under the Securities Act and no stop order preventing or suspending the effectiveness
of the Registration Statement or suspending or preventing the use of any Preliminary Prospectus or the Prospectus, has been issued
by the Commission and no proceedings for that purpose have been instituted or are threatened under the Securities Act. Any required
filing of any Preliminary Prospectus and/or the Prospectus and any supplement thereto pursuant to Rule 424(b) of the Rules has
been or will be made in the manner and within the time period required by such Rule 424(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
The documents incorporated by reference in the Registration Statement, any Preliminary Prospectus and the Prospectus, at the time
they became effective or were filed with the Commission, as the case may be, complied in all material respects with the requirements
of the Securities Act or the Exchange Act, as applicable, and the rules and regulations of the Commission thereunder, and none
of such documents contained an untrue statement of a material fact or omitted to state a material fact required to be stated therein
or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading,
and any further documents so filed and incorporated by reference in the Registration Statement, any Preliminary Prospectus and
the Prospectus, when such documents become effective or are filed with the Commission, as the case may be, will conform in all
material respects to the requirements of the Securities Act or the Exchange Act, as applicable, and the rules and regulations
of the Commission thereunder and will not contain an untrue statement of a material fact or omit to state a material fact required
to be stated therein or necessary to make the statements therein, in light of the circumstances under which they are made, not
misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
The financial statements of the Company (including all notes and schedules thereto) included or incorporated by reference in the
Registration Statement, the Statutory Prospectus and Prospectus present fairly the financial position of the Company and its consolidated
subsidiaries at the dates indicated and the statement of operations, stockholders&rsquo; equity and cash flows of the Company
and its consolidated subsidiaries for the periods specified; and such financial statements and related schedules and notes thereto,
and the unaudited financial information filed with the Commission as part of the Registration Statement, have been prepared in
conformity with generally accepted accounting principles, consistently applied throughout the periods involved. The summary and
selected financial data, if any, included or incorporated by reference in the Statutory Prospectus and Prospectus present fairly
the information shown therein as at the respective dates and for the respective periods specified and have been presented on a
basis consistent with the consolidated financial statements set forth in the Prospectus and other financial information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
GBH CPAs, PC (the &ldquo;Auditor&rdquo;) whose reports are filed with the Commission as a part of the Registration Statement,
are and, during the periods covered by their reports, were independent public accountants as required by the Securities Act and
the Rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
The Company and each of its subsidiaries, including each entity (corporation, partnership, joint venture, association or other
business organization) controlled directly or indirectly by the Company (each, a &ldquo;subsidiary&rdquo;), is duly organized,
validly existing and in good standing under the laws of their respective jurisdictions of incorporation or organization and each
such entity has all requisite power and authority to carry on its business as is currently being conducted as described in the
Statutory Prospectus and the Prospectus, and to own, lease and operate its properties. All of the issued shares of capital stock
of, or other ownership interests in, each subsidiary have been duly and validly authorized and issued and are fully paid and non-assessable
and are owned, directly or indirectly, by the Company, free and clear of any lien, charge, mortgage, pledge, security interest,
claim, limitation on voting rights, equity, trust or other encumbrance, preferential arrangement, defect or restriction of any
kind whatsoever. The Company and each of its subsidiaries is duly qualified to do business and is in good standing as a foreign
corporation in each jurisdiction in which the nature of the business conducted by it or location of the assets or properties owned,
leased or licensed by it requires such qualification, except for such jurisdictions where the failure to so qualify individually
or in the aggregate would not have a material adverse effect on the assets, properties, condition, financial or otherwise, or
in the results of operations, business affairs or business prospects of the Company and its subsidiaries considered as a whole
(a &ldquo;Material Adverse Effect&rdquo;); and to the Company&rsquo;s knowledge, no proceeding has been instituted in any such
jurisdiction revoking, limiting or curtailing, or seeking to revoke, limit or curtail, such power and authority or qualification.
The Company does not own, lease or license any asset or property or conduct any business outside the United States of America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
The Company has, in accordance with Rule 415(a)(6) of the Rules, prior to the third anniversary of the initial effective date
of the Registration Statement, filed a new shelf registration statement relating to the Securities, in a form satisfactory to
the Representative and has taken all other action necessary or appropriate to permit the public offering and sale of the Securities
to continue as contemplated in the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#9;The
Company and each of its subsidiaries has all requisite corporate power and authority, and all necessary authorizations, approvals,
consents, orders, licenses, certificates and permits of and from all governmental or regulatory bodies or any other person or
entity (collectively, the &ldquo;Permits&rdquo;), to own, lease and license its assets and properties and conduct its business,
all of which are valid and in full force and effect, except where the lack of such Permits, individually or in the aggregate,
would not have a Material Adverse Effect. The Company and each of its subsidiaries has fulfilled and performed in all material
respects all of its obligations with respect to such Permits and no event has occurred that allows, or after notice or lapse of
time would allow, revocation or termination thereof or results in any other material impairment of the rights of the Company thereunder.
Except as may be required under the Securities Act and state and foreign Blue Sky laws, no other Permits are required to enter
into, deliver and perform this Agreement and to issue and sell the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
(i) At the earliest time after the filing of the Registration Statement that the Company or another offering participant made
a <I>bona fide</I> offer (within the meaning of Rule&nbsp;164(h)(2) of the Rules) of the Securities and (ii) at the date hereof<B><I>,
</I></B>the Company was an &ldquo;ineligible issuer,&rdquo; as defined in Rule&nbsp;405 of the Rules. As a result, the Company
is not eligible to use any &ldquo;issuer free writing prospectus&rdquo; as defined in Rule 433 under the Securities Act in connection
with the offering of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)&#9;The
Company and each of its subsidiaries owns or possesses legally enforceable rights to use all patents, patent rights, inventions,
trademarks, trademark applications, trade names, service marks, copyrights, copyright applications, licenses, know-how and other
similar rights and proprietary knowledge (collectively, &ldquo;Intangibles&rdquo;) necessary for the conduct of its business.
Neither the Company nor any of its subsidiaries has received any notice of, or is not aware of, any infringement of or conflict
with asserted rights of others with respect to any Intangibles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
The Company and each of its subsidiaries has good and marketable title in fee simple to all real property, and good and marketable
title to all other property owned by it, in each case free and clear of all liens, encumbrances, claims, security interests and
defects, except such as do not materially affect the value of such property and do not materially interfere with the use made
or proposed to be made of such property by the Company and its subsidiaries. All property held under lease by the Company and
its subsidiaries is held by them under valid, existing and enforceable leases, free and clear of all liens, encumbrances, claims,
security interests and defects, except such as are not material and do not materially interfere with the use made or proposed
to be made of such property by the Company and its subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
Subsequent to the respective dates as of which information is given in the Registration Statement, the Statutory Prospectus and
the Prospectus, (i) there has not been any event which could have a Material Adverse Effect; (ii) neither the Company nor any
of its subsidiaries has sustained any loss or interference with its assets, businesses or properties (whether owned or leased)
from fire, explosion, earthquake, flood or other calamity, whether or not covered by insurance, or from any labor dispute or any
court or legislative or other governmental action, order or decree which would have a Material Adverse Effect; and (iii) since
the date of the latest balance sheet included in the Registration Statement and the Prospectus, neither the Company nor its subsidiaries
has (A) issued any securities or incurred any liability or obligation, direct or contingent, for borrowed money, except such liabilities
or obligations incurred in the ordinary course of business, (B) entered into any transaction not in the ordinary course of business
or (C) except for regular dividends on the Common Stock in amounts per share that are consistent with past practice, declared
or paid any dividend or made any distribution on any shares of its stock or redeemed, purchased or otherwise acquired or agreed
to redeem, purchase or otherwise acquire any shares of its capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
There is no document, contract or other agreement required to be described in the Registration Statement, the Statutory Prospectus
or the Prospectus or to be filed as an exhibit to the Registration Statement which is not described or filed as required by the
Securities Act or Rules. Each description of a contract, document or other agreement in the Registration Statement, the Statutory
Prospectus or the Prospectus accurately reflects in all respects the terms of the underlying contract, document or other agreement.
Each contract, document or other agreement described in the Registration Statement, the Statutory Prospectus or the Prospectus
or listed in the Exhibits to the Registration Statement or incorporated by reference is in full force and effect and is valid
and enforceable by and against the Company or its subsidiary, as the case may be, in accordance with its terms. Neither the Company
nor any of its subsidiaries, if a subsidiary is a party, nor to the Company&rsquo;s knowledge, any other party is in default in
the observance or performance of any term or obligation to be performed by it under any such agreement, and no event has occurred
which with notice or lapse of time or both would constitute such a default, in any such case which default or event, individually
or in the aggregate, would have a Material Adverse Effect. No default exists, and no event has occurred which with notice or lapse
of time or both would constitute a default, in the due performance and observance of any term, covenant or condition, by the Company
or its subsidiary, if a subsidiary is a party thereto, of any other agreement or instrument to which the Company or any of its
subsidiaries is a party or by which Company or its properties or business or a subsidiary or its properties or business may be
bound or affected which default or event, individually or in the aggregate, would have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
The statistical and market related data included or incorporated by reference in the Registration Statement, the Statutory Prospectus
or the Prospectus are based on or derived from sources that the Company believes to be reliable and accurate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)&#9;&#9;Neither
the Company nor any subsidiary (i) is in violation of its certificate or articles of incorporation, by-laws, certificate of formation,
limited liability company agreement, partnership agreement or other organizational documents, (ii) is in default under, and no
event has occurred which, with notice or lapse of time, or both, would constitute a default under, or result in the creation or
imposition of any lien, charge, mortgage, pledge, security interest, claim, limitation on voting rights, equity, trust or other
encumbrance, preferential arrangement, defect or restriction of any kind whatsoever, upon, any property or assets of the Company
or any subsidiary pursuant to, any bond, debenture, note, indenture, mortgage, deed of trust, loan agreement or other agreement
or instrument to which it is a party or by which it is bound or to which any of its properties or assets is subject or (iii) is
in violation of any statute, law, rule, regulation, ordinance, directive, judgment, decree or order of any judicial, regulatory
or other legal or governmental agency or body, foreign or domestic, except (in the case of clauses (ii) and (iii) above) for violations
or defaults that could not (individually or in the aggregate) reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
This Agreement has been duly authorized, executed and delivered by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)
Neither the execution, delivery and performance of this Agreement and the Warrants by the Company nor the consummation of any
of the transactions contemplated hereby (including, without limitation, the issuance and sale by the Company of the Shares and
the Warrants) will give rise to a right to terminate or accelerate the due date of any payment due under, or conflict with or
result in the breach of any term or provision of, or constitute a default (or an event which with notice or lapse of time or both
would constitute a default) under, or require any consent or waiver under, or result in the execution or imposition of any lien,
charge or encumbrance upon any properties or assets of the Company or its subsidiaries pursuant to the terms of, any indenture,
mortgage, deed of trust or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which
either the Company or its subsidiaries or any of their properties or businesses is bound, or any franchise, license, permit, judgment,
decree, order, statute, rule or regulation applicable to the Company or any of its subsidiaries or violate any provision of the
charter or by-laws of the Company or any of its subsidiaries, except for such consents or waivers which have already been obtained
and are in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)
The Company has authorized and outstanding capital stock as set forth under the caption &ldquo;Description of Securities We Are
Offering&rdquo; in the Statutory Prospectus and the Prospectus. The certificates evidencing the Shares and the Warrants are in
due and proper legal form and have been duly authorized for issuance by the Company. All of the issued and outstanding shares
of Common Stock have been duly and validly issued and are fully paid and nonassessable. There are no statutory preemptive or other
similar rights to subscribe for or to purchase or acquire any shares of Common Stock of the Company or any of its subsidiaries
or any such rights pursuant to its Certificate of Incorporation or by-laws or any agreement or instrument to or by which the Company
or any of its subsidiaries is a party or bound. The Company has reserved and kept available for the exercise of the Warrants such
number of authorized but unissued shares as are sufficient to permit the exercise in full of the Warrants. The Shares, when issued
and sold pursuant to this Agreement, and the Warrant Shares, when issued and sold pursuant to the Warrants, will be duly and validly
issued, fully paid and nonassessable and none of them will be issued in violation of any preemptive or other similar right. Except
as disclosed in the Registration Statement, the Statutory Prospectus and the Prospectus, there is no outstanding option, warrant
or other right calling for the issuance of, and there is no commitment, plan or arrangement to issue, any share of stock of the
Company or any of its subsidiaries or any security convertible into, or exercisable or exchangeable for, such stock. The exercise
price of each option to acquire Common Stock (each, a &ldquo;Company Stock Option&rdquo;) is no less than the fair market value
of a share of Common Stock as determined on the date of grant of such Company Stock Option. All grants of Company Stock Options
were validly issued and properly approved by the Board of Directors of the Company or the Compensation Committee thereof in material
compliance with all applicable laws and the terms of the plans under which such Company Stock Options were issued and were recorded
on the Company financial statements, including the documents incorporated by reference in the Registration Statement, the Statutory
Prospectus and the Prospectus, in accordance with GAAP, and no such grants involved any &ldquo;back dating&rdquo;, &ldquo;forward
dating,&rdquo; &ldquo;spring loading&rdquo; or similar practices with respect to the effective date of grant. The Common Stock,
the Shares and the Warrants conform in all material respects to all statements in relation thereto contained in the Registration
Statement, the Statutory Prospectus and the Prospectus. All outstanding shares of capital stock of each of the Company&rsquo;s
subsidiaries have been duly authorized and validly issued, and are fully paid and nonassessable and are owned directly by the
Company or by another wholly-owned subsidiary of the Company free and clear of any security interests, liens, encumbrances, equities
or claims, other than those described in the Statutory Prospectus and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)
No holder of any security of the Company has any right, which has not been waived, to have any security owned by such holder included
in the Registration Statement or to demand registration of any security owned by such holder for a period of 180 days after the
date of this Agreement. Each director and executive officer of the Company and each stockholder of the Company listed on Schedule
II hereto has delivered to the Representative his enforceable written lock-up agreement in the form attached to this Agreement
as Exhibit A hereto (&ldquo;Lock-Up Agreement&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)
There are no legal or governmental proceedings pending to which the Company or any of its subsidiaries is a party or of which
any property of the Company or any of its subsidiaries is the subject which, if determined adversely to the Company or any of
its subsidiaries could individually or in the aggregate have a Material Adverse Effect; and, to the knowledge of the Company,
no such proceedings are threatened or contemplated by governmental authorities or threatened by others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
All necessary corporate action has been duly and validly taken by the Company and to authorize the execution, delivery and performance
of this Agreement and the Warrants, and the issuance and sale of the Shares, the Warrants and the Warrant Shares by the Company.
The Warrants have been duly and validly authorized and, upon the execution and delivery thereof by the Company on the Closing
Date, will constitute legal, valid and binding obligations of the Company enforceable against the Company in accordance with their
terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)
Neither the Company nor any of its subsidiaries is involved in any labor dispute nor, to the knowledge of the Company, is any
such dispute threatened, which dispute would have a Material Adverse Effect. The Company is not aware of any existing or imminent
labor disturbance by the employees of any of its principal suppliers or contractors which would have a Material Adverse Effect.
The Company is not aware of any threatened or pending litigation between the Company or its subsidiaries and any of its executive
officers which, if adversely determined, could have a Material Adverse Effect and has no reason to believe that such officers
will not remain in the employment of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
No transaction has occurred between or among the Company and any of its officers or directors, shareholders or any affiliate or
affiliates of any such officer or director or shareholder that is required to be described in and is not described in the Registration
Statement, the Statutory Prospectus and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)
The Company has not taken, nor will it take, directly or indirectly, any action designed to or which might reasonably be expected
to cause or result in, or which has constituted or which might reasonably be expected to constitute, the stabilization or manipulation
of the price of the Common Stock or any security of the Company to facilitate the sale or resale of any of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)
The Company and each of its subsidiaries has filed all Federal, state, local and foreign tax returns which are required to be
filed through the date hereof, which returns are true and correct in all material respects or has received timely extensions thereof,
and has paid all taxes shown on such returns and all assessments received by it to the extent that the same are material and have
become due. There are no tax audits or investigations pending, which if adversely determined would have a Material Adverse Effect;
nor are there any material proposed additional tax assessments against the Company or any of its subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)&#9;The
Common Stock is registered pursuant to Section 12(b) of the Exchange Act and is listed on the NYSE American. The Company has taken
no action designed to, or likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act
or listing of the Common Stock on the NYSE American. There is no action pending by the Company or, to the Company&rsquo;s knowledge,
by the NYSE American to delist the Common Stock from the NYSE American, nor has the Company received any notification that the
NYSE American is contemplating terminating such listing. The Company has submitted an Application for Listing of Additional Shares
with the NYSE American with respect to the Shares and the NYSE American has raised no objection with respect to the listing of
the Shares which has not been resolved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)
The books, records and accounts of the Company and its subsidiaries accurately and fairly reflect, the transactions in, and dispositions
of, the assets of, and the results of operations of, the Company and its subsidiaries. The Company and each of its subsidiaries
maintains a system of internal accounting controls sufficient to provide reasonable assurances that (i) transactions are executed
in accordance with management&rsquo;s general or specific authorizations, (ii) transactions are recorded as necessary to permit
preparation of financial statements in accordance with generally accepted accounting principles and to maintain asset accountability,
(iii) access to assets is permitted only in accordance with management&rsquo;s general or specific authorization and (iv) the
recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken
with respect to any differences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)&#9;The
Company has established and maintains disclosure controls and procedures (as such term is defined in Rule 13a-15 under the Exchange
Act), which: (i) are designed to ensure that material information relating to the Company is made known to the Company&rsquo;s
principal executive officer and its principal financial officer by others within the Company, particularly during the periods
in which the periodic reports required under the Exchange Act are required to be prepared; (ii) provide for the periodic evaluation
of the effectiveness of such disclosure controls and procedures at the end of the periods in which the periodic reports are required
to be prepared; and (iii) are effective in all material respects to perform the functions for which they were established.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)&#9;Based
on the evaluation of its disclosure controls and procedures, except as disclosed in the Statutory Prospectus and the Prospectus,
the Company is not aware of (i) any material weakness or significant deficiency in the design or operation of internal controls
which could adversely affect the Company&rsquo;s ability to record, process, summarize and report financial data or any material
weaknesses in internal controls; or (ii) any fraud, whether or not material, that involves management or other employees who have
a role in the Company&rsquo;s internal controls.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)&#9;
Except as described in the Statutory Prospectus and the Prospectus and as preapproved in accordance with the requirements set
forth in Section 10A of the Exchange Act, the Auditor has not been engaged by the Company to perform any &ldquo;prohibited activities&rdquo;
(as defined in Section 10A of the Exchange Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)&#9;Except
as described in the Statutory Prospectus and the Prospectus, there are no material off-balance sheet arrangements (as defined
in Item 303 of Regulation S-K) that have or are reasonably likely to have a material current or future effect on the Company&rsquo;s
financial condition, revenues or expenses, changes in financial condition, results of operations, liquidity, capital expenditures
or capital resources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)&#9;The
Company&rsquo;s Board of Directors has validly appointed an audit committee whose composition satisfies the requirements of Rule
803 of the NYSE American and the Board of Directors and/or the audit committee has adopted a charter that satisfies the requirements
of Rule 803 of the NYSE American. The audit committee has reviewed the adequacy of its charter within the past twelve months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)
There is and has been no failure on the part of the Company or any of its directors or officers, in their capacities as such,
to comply with any provision of the Sarbanes-Oxley Act, including, without limitation, Section 402 related to loans and Sections
302 and 906 related to certifications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#9;The
Company and its subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and
in such amounts as are customary in the businesses in which they are engaged or propose to engage after giving effect to the transactions
described in the Statutory Prospectus and the Prospectus; all policies of insurance and fidelity or surety bonds insuring the
Company or any of its subsidiaries or the Company&rsquo;s or its subsidiaries&rsquo; respective businesses, assets, employees,
officers and directors are in full force and effect; the Company and each of its subsidiaries are in compliance with the terms
of such policies and instruments in all material respects; and neither the Company nor any subsidiary of the Company has any reason
to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar
coverage from similar insurers as may be necessary to continue its business at a cost that is not materially greater than the
current cost. Neither the Company nor any of its subsidiaries has been denied any insurance coverage which it has sought or for
which it has applied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)&#9;Each
approval, consent, order, authorization, designation, declaration or filing of, by or with any regulatory, administrative or other
governmental body necessary in connection with the execution and delivery by the Company of this Agreement and the consummation
of the transactions herein contemplated required to be obtained or performed by the Company (except such additional steps as may
be required by the Financial Industry Regulatory Authority (&ldquo;FINRA&rdquo;) or may be necessary to qualify the Securities
for public offering by the Underwriters under the state securities or Blue Sky laws) has been obtained or made and is in full
force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk)&#9;There
are no affiliations with FINRA among the Company&rsquo;s officers, directors or, to the best of the knowledge of the Company,
any five percent or greater stockholder of the Company, except as set forth in the Registration Statement, the Statutory Prospectus
and the Prospectus or otherwise disclosed in writing to the Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)&#9;(i)
Each of the Company and each of its subsidiaries is in compliance in all material respects with all rules, laws and regulation
relating to the use, treatment, storage and disposal of toxic substances and protection of health or the environment (&ldquo;Environmental
Law&rdquo;) which are applicable to its business; (ii) neither the Company nor its subsidiaries has received any notice from any
governmental authority or third party of an asserted claim under Environmental Laws; (iii) each of the Company and each of its
subsidiaries has received all permits, licenses or other approvals required of it under applicable Environmental Laws to conduct
its business and is in compliance with all terms and conditions of any such permit, license or approval; (iv) to the Company&rsquo;s
knowledge, no facts currently exist that will require the Company or any of its subsidiaries to make future material capital expenditures
to comply with Environmental Laws; and (v) no property which is or has been owned, leased or occupied by the Company or its subsidiaries
has been designated as a Superfund site pursuant to the Comprehensive Environmental Response, Compensation of Liability Act of
1980, as amended (42 U.S.C. Section 9601, et. seq.) or otherwise designated as a contaminated site under applicable state or local
law. Neither the Company nor any of its subsidiaries has been named as a &ldquo;potentially responsible party&rdquo; under the
CERCLA 1980.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm)&#9;In
the ordinary course of its business, the Company periodically reviews the effect of Environmental Laws on the business, operations
and properties of the Company and its subsidiaries, in the course of which the Company identifies and evaluates associated costs
and liabilities (including, without limitation, any capital or operating expenditures required for clean-up, closure of properties
or compliance with Environmental Laws, or any permit, license or approval, any related constraints on operating activities and
any potential liabilities to third parties). On the basis of such review, the Company has reasonably concluded that such associated
costs and liabilities would not, singly or in the aggregate, have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn)&#9;The
Company is not and, after giving effect to the offering and sale of the Shares and the Warrants and the application of proceeds
thereof (including any cash exercise of the Warrants) as described in the Statutory Prospectus and the Prospectus, will not be
an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended (the &ldquo;Investment
Company Act&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oo)
The Company or any other person associated with or acting on behalf of the Company including, without limitation, any director,
officer, agent or employee of the Company or its subsidiaries, has not, directly or indirectly, while acting on behalf of the
Company or its subsidiaries (i) used any corporate funds for unlawful contributions, gifts, entertainment or other unlawful expenses
relating to political activity; (ii)&nbsp;made any unlawful payment to foreign or domestic government officials or employees or
to foreign or domestic political parties or campaigns from corporate funds; (iii) violated any provision of the Foreign Corrupt
Practices Act of 1977, as amended; or (iv) made any other unlawful payment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(pp)&#9;The
operations of the Company and its subsidiaries are and have been conducted at all times in compliance with applicable financial
recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money
laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or
guidelines, issued, administered or enforced by any governmental agency (collectively, the &ldquo;Money Laundering Laws&rdquo;)
and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving
the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending, or to the best knowledge of the Company,
threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(qq)&#9;Neither
the Company nor any of its subsidiaries nor, to the knowledge of the Company, any director, officer, agent, employee or affiliate
of the Company or any of its subsidiaries is currently subject to any U.S. sanctions administered by the Office of Foreign Assets
Control of the U.S. Treasury Department (&ldquo;OFAC&rdquo;); and the Company will not directly or indirectly use the proceeds
of the offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other
person or entity, for the purpose of financing the activities of any person currently subject to any U.S. sanctions administered
by OFAC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(rr)
&#9;Except as described in the Statutory Prospectus and the Prospectus, the Company has not sold or issued any shares of Common
Stock during the six-month period preceding the date of the Prospectus, including any sales pursuant to Rule 144A under, or Regulations
D or S of, the Securities Act, other than shares issued pursuant to employee benefit plans, qualified stock options plans or other
employee compensation plans or pursuant to outstanding options, rights or warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ss)
&#9;The Company has fulfilled its obligations, if any, under the minimum funding standards of Section 302 of the U.S. Employee
Retirement Income Security Act of 1974 (&ldquo;ERISA&rdquo;) and the regulations and published interpretations thereunder with
respect to each &ldquo;plan&rdquo; as defined in Section 3(3) of ERISA and such regulations and published interpretations in which
its employees are eligible to participate and each such plan is in compliance in all material respects with the presently applicable
provisions of ERISA and such regulations and published interpretations. No &ldquo;Reportable Event&rdquo; (as defined in 12 ERISA)
has occurred with respect to any &ldquo;Pension Plan&rdquo; (as defined in ERISA) for which the Company could have any liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(tt)&#9;
None of the Company, its directors or its officers has distributed nor will distribute prior to the later of (i) the Closing Date
and (ii) completion of the distribution of the Shares and the Warrants, any offering material in connection with the offering
and sale of the Shares and the Warrants other than any Preliminary Prospectus, the Prospectus, the Registration Statement and
other materials, if any, permitted by the Securities Act and consistent with Section 3(d) below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(uu)&nbsp;
The Company is an &ldquo;emerging growth company,&rdquo; as defined in Section 2(a) of the Securities Act (an &ldquo;Emerging
Growth Company&rdquo;). &ldquo;Testing-the-Waters Communication&rdquo; means any oral or written communication with potential
investors undertaken in reliance on Section 5(d) of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vv)
The Company (a) has not alone engaged in any Testing-the-Waters Communication and (b) has not authorized anyone other than the
Underwriter to engage in Testing-the-Waters Communications. The Company reconfirms that the Underwriter has been authorized to
act on its behalf in undertaking Testing-the-Waters Communications. The Company has not distributed any Written Testing-the-Waters
Communications (as defined herein). &ldquo;Written Testing-the-Waters Communication&rdquo; means any Testing-the-Waters Communication
that is a written communication within the meaning of Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ww)
Except as described in the Registration Statement, the General Disclosure Package and the Prospectus, the Company and each of
its subsidiaries: (A) are and at all times have been, in material compliance with all statutes, rules and regulations applicable
to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion,
sale, offer for sale, storage, import, export or disposal of any product sold, under development, manufactured or distributed
by the Company or any subsidiary (&ldquo;Applicable Regulatory Laws&rdquo;); (B) have not received any Form 483 from the United
States Food and Drug Administration (&ldquo;FDA&rdquo;), notice of adverse finding, warning letter, or other correspondence or
written notice from the FDA, the Drug Enforcement Administration (&ldquo;DEA&rdquo;) or any other federal, state, local, national
or foreign governmental or regulatory authority alleging or asserting noncompliance with any Applicable Regulatory Laws or any
licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such
Applicable Regulatory Laws (&ldquo;Authorizations&rdquo;); (C) possess all Authorizations, if any, and such Authorizations are
valid and in full force and effect and neither the Company nor any subsidiary is in material violation of any term of any such
Authorizations; (D) have not received written notice of any proceeding, hearing, enforcement, investigation, arbitration or other
action from the FDA, the DEA, or any other federal, state, local, national or foreign governmental or regulatory authority or
third party alleging that any product, operation or activity is in violation of any Applicable Regulatory Laws or Authorizations
and has no knowledge that the FDA, the DEA or any other federal, state, local, national or foreign governmental or regulatory
authority or third party is considering any such proceeding; (E) have not received written notice that the FDA, DEA or any other
federal, state, local, national or foreign governmental or regulatory authority has taken, is taking or intends to take action
to limit, suspend, modify or revoke any Authorizations and has no knowledge that the FDA, DEA or any other federal, state, local,
national or foreign governmental or regulatory authority is considering such action; (F) have filed, obtained, maintained or submitted
all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by
any Applicable Regulatory Laws or Authorizations except where the failure to file such reports, documents, forms, notices, applications,
records, claims, submissions and supplements or amendments would not result in a Material Adverse Effect on the Company and its
subsidiaries, taken as a whole, and that all such reports, documents, forms, notices, applications, records, claims, submissions
and supplements or amendments were complete and correct on the date filed (or were corrected or supplemented by a subsequent submission);
and (G) has, and, if still pending, is, to the Company&rsquo;s knowledge, conducting all clinical and preclinical studies in all
material respects in accordance with experimental protocols, procedures and controls generally used by qualified experts in the
clinical or preclinical study of new drugs or diagnostics as applied to comparable products to those being developed by the Company.
The descriptions of the results of such studies, trials and tests contained in the Registration Statement, the Statutory Prospectus
and the Prospectus are accurate and complete in all material respects, and except as set forth in the Registration Statement,
the Statutory Prospectus and the Prospectus, the Company has no knowledge of any other trials, studies or tests, the results of
which the Company believes reasonably calls into question the clinical trials, results described or referred to in the Registration
Statement and the Prospectus when viewed in the context in which such results are described and the clinical state of development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<U>Conditions of the Underwriters&rsquo; Obligations</U>. The obligations of the Underwriters under this Agreement are several
and not joint. The respective obligations of the Underwriters to purchase the Shares and the Warrants are subject to each of the
following terms and conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
&#9;The Prospectus shall have been timely filed with the Commission in accordance with Section 4(a) of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
No order preventing or suspending the use of any Preliminary Prospectus or the Prospectus shall have been or shall be in effect
and no order suspending the effectiveness of the Registration Statement shall be in effect and no proceedings for such purpose
shall be pending before or threatened by the Commission, and any requests for additional information on the part of the Commission
(to be included in the Registration Statement or the Prospectus or otherwise) shall have been complied with to the satisfaction
of the Commission and the Representative. If the Company has elected to rely upon Rule 430B, Rule 430B information previously
omitted from the effective Registration Statement pursuant to Rule 430B shall have been transmitted to the Commission for filing
pursuant to Rule 424(b) within the prescribed time period and the Company shall have provided evidence satisfactory to the Representative
of such timely filing, or a post-effective amendment providing such information shall have been promptly filed and declared effective
in accordance with the requirements of Rule 430B.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The representations and warranties of the Company contained in this Agreement and in the certificate delivered pursuant to Section
3(d) shall be true and correct when made and on and as of the Closing Date as if made on such date. The Company shall have performed
all covenants and agreements and satisfied all the conditions contained in this Agreement required to be performed or satisfied
by them at or before the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
The Representative shall have received on the Closing Date a certificate, addressed to the Representative and dated the Closing
Date, of the chief executive or chief operating officer and the chief financial officer or chief accounting officer of the Company
to the effect that: (i) the representations, warranties and agreements of the Company in this Agreement were true and correct
when made and are true and correct as of the Closing Date; (ii) the Company has performed all covenants and agreements and satisfied
all conditions contained herein; (iii) they have carefully examined the Registration Statement, the Prospectus, the General Disclosure
Package, and in their opinion (A) as of the Effective Date the Registration Statement and Prospectus did not include, and as of
the Applicable Time, the General Disclosure Package did not include any untrue statement of a material fact and did not omit to
state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances
under which they were made, not misleading, and (B) since the Effective Date no event has occurred which should have been set
forth in a supplement or otherwise required an amendment to the Registration Statement, the Statutory Prospectus or the Prospectus;
(iv) no stop order suspending the effectiveness of the Registration Statement has been issued and, to their knowledge, no proceedings
for that purpose have been instituted or are pending under the Securities Act and (v) there has not occurred any material adverse
change in the assets, properties, condition, financial or otherwise, or in the results of operations, business affairs or business
prospects of the Company and its subsidiaries considered as a whole.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
The Representative shall have received: (i) simultaneously with the execution of this Agreement a signed letter from the Auditor
addressed to the Representative and dated the date of this Agreement, in form and substance reasonably satisfactory to the Representative,
containing statements and information of the type ordinarily included in accountants&rsquo; &ldquo;comfort letters&rdquo; to underwriters
with respect to the financial statements and certain financial information contained in the Registration Statement and the Disclosure
Package, and (ii) on the Closing Date, a signed letter from the Auditor addressed to the Representative and dated the date of
the Closing Date, in form and substance reasonably satisfactory to the Representative containing statements and information of
the type ordinarily included in accountants&rsquo; &ldquo;comfort letters&rdquo; to underwriters with respect to the financial
statements and certain financial information contained in the Registration Statement and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
The Representative shall have received on the Closing Date from The Matt Law Firm, PLLC, counsel for the Company, an opinion and
negative assurance statement, addressed to the Representative and dated the Closing Date, in form and substance reasonably satisfactory
to the Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
The Representative shall have received on the Closing Date from Wilmer Cutler Pickering Hale and Dorr LLP, intellectual property
counsel for the Company, an opinion and negative assurance statement, addressed to the Representative and dated the Closing Date,
in form and substance reasonably satisfactory to the Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
The Representative shall have received on the Closing Date from Lowenstein Sandler LLP, counsel for the Representative, an opinion
and negative assurance statement, addressed to the Representative and dated the Closing Date, in form and substance reasonably
satisfactory to the Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
All proceedings taken in connection with the sale of the Shares and the Warrants as herein contemplated shall be reasonably satisfactory
in form and substance to the Representative and its counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
On or prior to the execution and delivery of this Agreement, the Representative shall have received copies of the Lock-up Agreements
executed by each entity or person listed on Schedule II hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
The Company shall have submitted a Listing of Additional Shares Application with the NYSE American with respect to the Shares
and Warrant Shares and the NYSE American shall have raised no objection with respect to the listing of the Shares and Warrant
Shares which has not been resolved to the reasonable satisfaction of the Representative on or before the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
The Representative shall be reasonably satisfied that since the respective dates as of which information is given in the Registration
Statement, the Statutory Prospectus, the General Disclosure Package and the Prospectus, (i) there shall not have been any material
change in the capital stock of the Company or any material change in the indebtedness (other than in the ordinary course of business)
of the Company, (ii) except as set forth or contemplated by the Registration Statement, the Statutory Prospectus, the General
Disclosure Package or the Prospectus, no material oral or written agreement or other transaction shall have been entered into
by the Company that is not in the ordinary course of business or that could reasonably be expected to result in a material reduction
in the future earnings of the Company, (iii) no loss or damage (whether or not insured) to the property of the Company shall have
been sustained that had or could reasonably be expected to have a Material Adverse Effect, (iv) no legal or governmental action,
suit or proceeding affecting the Company or any of its properties that is material to the Company or that affects or could reasonably
be expected to affect the transactions contemplated by this Agreement shall have been instituted or threatened and (v) there shall
not have been any material change in the assets, properties, condition (financial or otherwise), or in the results of operations,
business affairs or business prospects of the Company or its subsidiaries considered as a whole that makes it impractical or inadvisable
in the Underwriter&rsquo;s judgment to proceed with the purchase or offering of the Shares and the Warrants as contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
On or before the Closing Date, FINRA shall have confirmed that it has not raised any objection with respect to the fairness and
reasonableness of the underwriting terms and agreements in connection with the offering of the Shares and the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
The Company shall have furnished or caused to be furnished to the Representative such further certificates or documents as the
Representative shall have reasonably requested.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<U>Covenants and other Agreements of the Company and the Underwriters</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Company covenants and agrees as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The Company shall prepare the Prospectus in a form approved by the Representative and file such Prospectus pursuant to Rule 424(b)
under the Securities Act not later than the Commission&rsquo;s close of business on the second business day following the execution
and delivery of this Agreement, or, if applicable, such earlier time as may be required by the Rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
The Company shall promptly advise the Representative in writing (A) when any post-effective amendment to the Registration Statement
shall have become effective or any supplement to the Prospectus shall have been filed, (B) of any request by the Commission for
any amendment of the Registration Statement or the Prospectus or for any additional information, (C) of the issuance by the Commission
of any stop order suspending the effectiveness of the Registration Statement or of any order preventing or suspending the use
of any preliminary prospectus or the institution or threatening of any proceeding for that purpose and (D) of the receipt by the
Company of any notification with respect to the suspension of the qualification of the Securities for sale in any jurisdiction
or the initiation or threatening of any proceeding for such purpose. The Company shall not file any amendment of the Registration
Statement or supplement to the Prospectus or any document incorporated by reference in the Registration Statement unless the Company
has furnished the Representative a copy for its review prior to filing and shall not file any such proposed amendment or supplement
to which the Representative reasonably objects. The Company shall use its best efforts to prevent the issuance of any such stop
order and, if issued, to obtain as soon as possible the withdrawal thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
If, at any time when a prospectus relating to the Securities (or, in lieu thereof, the notice referred to in Rule 173(a) of the
Rules) is required to be delivered under the Securities Act and any event occurs as a result of which the Prospectus as then amended
or supplemented would include any untrue statement of a material fact or omit to state any material fact necessary to make the
statements therein in the light of the circumstances under which they were made not misleading, or if it shall be necessary to
amend or supplement the Prospectus to comply with the Securities Act or the Rules, the Company promptly shall prepare and file
with the Commission, subject to the second sentence of paragraph (ii) of this Section 4(a), an amendment or supplement which shall
correct such statement or omission or an amendment which shall effect such compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
The Company shall make generally available to its security holders and to the Representative as soon as practicable, but not later
than 45 days after the end of the 12-month period beginning at the end of the fiscal quarter of the Company during which the Effective
Date occurs (or 90 days if such 12-month period coincides with the Company&rsquo;s fiscal year), an earning statement (which need
not be audited) of the Company, covering such 12-month period, which shall satisfy the provisions of Section 11(a) of the Securities
Act or Rule 158 of the Rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
The Company shall furnish to the Representative and its counsel for the Underwriters, without charge, signed copies of the Registration
Statement (including all exhibits thereto and amendments thereof) and to each other Underwriter a copy of the Registration Statement
(without exhibits thereto) and all amendments thereof and, so long as delivery of a prospectus by an Underwriter or dealer may
be required by the Securities Act or the Rules, as many copies of any Preliminary Prospectus, and the Prospectus and any amendments
thereof and supplements thereto as the Representative may reasonably request. If applicable, the copies of the Registration Statement,
preliminary prospectus, and Prospectus and each amendment and supplement thereto furnished to the Underwriters will be identical
to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by
Regulation S-T.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
The Company shall cooperate with the Representative and its counsel in endeavoring to qualify the Securities for offer and sale
in connection with the offering under the laws of such jurisdictions as the Representative may designate and shall maintain such
qualifications in effect so long as required for the distribution of the Shares and the Warrants; provided, however, that the
Company shall not be required in connection therewith, as a condition thereof, to qualify as a foreign corporation or to execute
a general consent to service of process in any jurisdiction or subject itself to taxation as doing business in any jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
The Company, during the period when the Prospectus (or in lieu thereof, the notice referred to in Rule 173(a) of the Rules) is
required to be delivered under the Securities Act and the Rules or the Exchange Act, will file all reports and other documents
required to be filed with the Commission pursuant to Section 13, 14 or 15 of the Exchange Act within the time periods required
by the Exchange Act and the regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)
Without the prior written consent of the Representative, for a period of 90 days after the date of this Agreement, the Company
shall not issue, sell or register with the Commission (other than on Form S-8 or on any successor form), or otherwise dispose
of, directly or indirectly, any equity securities of the Company (or any securities convertible into, exercisable for or exchangeable
for equity securities of the Company), except for (i) the issuance of the Securities pursuant to the Registration Statement; (ii)
the issuance of shares pursuant to the Company&rsquo;s existing stock option plan or bonus plan as described in the Registration
Statement and the Prospectus; and (iii) commencing on the 31st day after the Closing Date, shares of its Common Stock pursuant
to the At-the-Market Issuance Sales Agreement between the Company and FBR &amp; Co., LLC, or any successor agreement. In the event
that during this period, (A) any shares are issued pursuant to the Company&rsquo;s existing stock option plan or bonus plan that
are exercisable during such 90 day period or (B) any registration is effected on Form S-8 or on any successor form relating to
shares that are exercisable during such 90 period, the Company shall obtain the written agreement of such grantee or purchaser
or holder of such registered securities that, for a period of 90 days after the date of this Agreement, such person will not,
without the prior written consent of the Representative, offer for sale, sell, distribute, grant any option for the sale of, or
otherwise dispose of, directly or indirectly, or exercise any registration rights with respect to, any shares of Common Stock
(or any securities convertible into, exercisable for, or exchangeable for any shares of Common Stock) owned by such person. Notwithstanding
the foregoing, the Company represents and warrants that each such grantee or purchaser or holder of such registered securities
shall be subject to similar lockup restrictions as set forth on Exhibit A attached hereto and the Company shall enforce such rights
and impose stop-transfer restrictions on any such sale or other transfer or disposition of such shares until the end of the applicable
period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)
On or before completion of this offering, the Company shall make all filings required under applicable securities laws and by
the NYSE American.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
Prior to the Closing Date, the Company will issue no press release or other communications directly or indirectly and hold no
press conference with respect to the Company, the condition, financial or otherwise, or the earnings, business affairs or business
prospects of any of them, or the offering of the Securities without the prior written consent of the Representative unless in
the judgment of the Company and its counsel, and after notification to the Representative, such press release or communication
is required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xi)
The Company will apply the net proceeds from the offering of the Shares and the Warrants in the manner set forth under &ldquo;Use
of Proceeds&rdquo; in the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xii)
The Company will promptly notify the Representative if the Company ceases to be an Emerging Growth Company at any time prior to
the later of (a)&nbsp;completion of the distribution of the Shares within the meaning of the Securities Act and (b)&nbsp;completion
of the 90-day restricted period referred to in Section&nbsp;4(a)(viii) hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiii)
If at any time following the distribution of any Written Testing-the-Waters Communication there occurred or occurs an event or
development as a result of which such Written Testing-the-Waters Communication included or would include an untrue statement of
a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light
of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representative and
will promptly amend or supplement, at its own expense, such Written Testing-the-Waters Communication to eliminate or correct such
untrue statement or omission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Company agrees to pay, or reimburse if paid by the Representative, whether or not the transactions contemplated hereby are
consummated or this Agreement is terminated, all costs and expenses incident to the public offering of the Securities and the
performance of the obligations of the Company under this Agreement including those relating to: (i) the preparation, printing,
reproduction filing and distribution of the Registration Statement including all exhibits thereto, each Preliminary Prospectus,
the Prospectus, all amendments and supplements thereto and any document incorporated by reference therein, and the printing, filing
and distribution of this Agreement; (ii) the preparation and delivery of certificates for the Shares and the Warrants to or as
directed by the Underwriters (iii) the registration or qualification of the Securities for offer and sale under the securities
or Blue Sky laws of the various jurisdictions referred to in Section 4(a)(vi) of this Agreement, including the reasonable fees
and disbursements of counsel for the Representative in connection with such registration and qualification and the preparation,
printing, distribution and shipment of preliminary and supplementary Blue Sky memoranda; (iv) the furnishing (including costs
of shipping and mailing) to the Representative and to the Underwriters of copies of each Preliminary Prospectus, the Prospectus
and all amendments or supplements to the Prospectus, and of the several documents required by this Section to be so furnished,
as may be reasonably requested for use in connection with the offering and sale of the Shares and the Warrants by the Underwriters
or by dealers to whom Shares and Warrants may be sold; (v) the filing fees of FINRA in connection with its review of the terms
of the public offering and reasonable fees and disbursements of counsel for the Representative in connection with such review;
(vi) inclusion of the Shares and the Warrant Shares for listing on the NYSE American; and (vii) all transfer taxes, if any, with
respect to the sale and delivery of the Shares and the Warrants by the Company to the Underwriters. The Company will reimburse
the Representative for its reasonable out-of-pocket costs and expenses, including its legal fees and disbursements, in connection
with the purchase and sale of the Shares and the Warrants contemplated hereby in an amount not to exceed $85,000 (including amounts
payable pursuant to clauses (iii) and (v) above). Subject to the provisions of Section 7, the Underwriters agree to pay, whether
or not the transactions contemplated hereby are consummated or this Agreement is terminated, all costs and expenses incident to
the performance of the obligations of the Underwriters under this Agreement not payable by the Company pursuant to this paragraph,
including, without limitation, the fees and disbursements of counsel for the Underwriters in excess of the Company&rsquo;s reimbursement
obligation as set forth above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The Company acknowledges and agrees that each of the Underwriters has acted and is acting solely in the capacity of a principal
in an arm&rsquo;s length transaction between the Company, on the one hand, and the Underwriters, on the other hand, with respect
to the offering of the Shares and the Warrants contemplated hereby (including in connection with determining the terms of the
offering) and not as a financial advisor, agent or fiduciary to the Company or any other person. Additionally, the Company acknowledges
and agrees that the Underwriters have not and will not advise the Company or any other person as to any legal, tax, investment,
accounting or regulatory matters in any jurisdiction. The Company has consulted with its own advisors concerning such matters
and shall be responsible for making its own independent investigation and appraisal of the transactions contemplated hereby, and
the Underwriters shall have no responsibility or liability to the Company or any other person with respect thereto, whether arising
prior to or after the date hereof. Any review by the Underwriters of the Company, the transactions contemplated hereby or other
matters relating to such transactions have been and will be performed solely for the benefit of the Underwriters and shall not
be on behalf of the Company. The Company agrees that it will not claim that the Underwriters, or any of them, has rendered advisory
services of any nature or respect, or owes a fiduciary duty to the Company or any other person in connection with any such transaction
or the process leading thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<U>Indemnification</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Company agrees to indemnify and hold harmless each Underwriter, its officers and employees and each person, if any, who controls
any Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act against any and all losses,
claims, damages and liabilities, joint or several (including any reasonable investigation, legal and other expenses incurred in
connection with, and any amount paid in settlement of, any action, suit or proceeding or any claim asserted), to which they, or
any of them, may become subject under the Securities Act, the Exchange Act or other Federal or state law or regulation, at common
law or otherwise, insofar as such losses, claims, damages or liabilities arise out of or are based upon any untrue statement or
alleged untrue statement of a material fact contained in any preliminary prospectus, the Registration Statement, the Statutory
Prospectus, the Prospectus, any amendment thereof or supplement thereto, any Written Testing-the-Waters Communication, or in any
Blue Sky application or other information or other documents executed by the Company filed in any state or other jurisdiction
to qualify any or all of the Securities under the securities laws thereof (any such application, document or information being
hereinafter referred to as a &ldquo;Blue Sky Application&rdquo;) or arise out of or are based upon any omission or alleged omission
to state therein a material fact required to be stated therein or necessary to make the statements therein (except in the case
of the Registration Statement, in light of the circumstances under which they were made) not misleading; provided, however, that
such indemnity shall not inure to the benefit of any Underwriter (or any person controlling such Underwriter) on account of any
losses, claims, damages or liabilities arising from the sale of the Shares and the Warrants to any person by such Underwriter
if such untrue statement or omission or alleged untrue statement or omission was made in such preliminary prospectus, the Registration
Statement, the Prospectus, the Statutory Prospectus, or such amendment or supplement thereto, any Written Testing-the-Waters Communication,
or in any Blue Sky Application in reliance upon and in conformity with the Underwriter Information. This indemnity agreement will
be in addition to any liability which the Company may otherwise have.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Each Underwriter, severally and not jointly, agrees to indemnify and hold harmless the Company and each person, if any, who controls
the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, each director of the Company,
and each officer of the Company who signs the Registration Statement, against any losses, claims, damages or liabilities to which
such party may become subject, under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or
actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of a material fact
contained in any preliminary prospectus, the Registration Statement or the Prospectus, or any amendment or supplement thereto,
or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein
or necessary to make the statements therein not misleading, in each case to the extent, but only to the extent, that such untrue
statement or alleged untrue statement or omission or alleged omission was made in any Preliminary Prospectus, the Registration
Statement, the Statutory Prospectus or the Prospectus or any such amendment or supplement in reliance upon and in conformity with
the Underwriter Information; provided, however, that the obligation of each Underwriter to indemnify the Company (including any
controlling person, director or officer thereof) shall be limited to the amount of the underwriting discount and commissions applicable
to the Shares and the Warrants to be purchased by such Underwriter hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Any party that proposes to assert the right to be indemnified under this Section will, promptly after receipt of notice of commencement
of any action, suit or proceeding against such party in respect of which a claim is to be made against an indemnifying party or
parties under this Section, notify each such indemnifying party of the commencement of such action, suit or proceeding, enclosing
a copy of all papers served. No indemnification provided for in Section 5(a) or 5(b) shall be available to any party who shall
fail to give notice as provided in this Section 5(c) if the party to whom notice was not given was unaware of the proceeding to
which such notice would have related and was prejudiced by the failure to give such notice but the omission so to notify such
indemnifying party of any such action, suit or proceeding shall not relieve it from any liability that it may have to any indemnified
party for contribution or otherwise than under this Section. In case any such action, suit or proceeding shall be brought against
any indemnified party and it shall notify the indemnifying party of the commencement thereof, the indemnifying party shall be
entitled to participate in, and, to the extent that it shall wish, jointly with any other indemnifying party similarly notified,
to assume the defense thereof, with counsel reasonably satisfactory to such indemnified party, and after notice from the indemnifying
party to such indemnified party of its election so to assume the defense thereof and the approval by the indemnified party of
such counsel, the indemnifying party shall not be liable to such indemnified party for any legal or other expenses, except as
provided below and except for the reasonable costs of investigation subsequently incurred by such indemnified party in connection
with the defense thereof. The indemnified party shall have the right to employ its counsel in any such action, but the fees and
expenses of such counsel shall be at the expense of such indemnified party unless (i) the employment of counsel by such indemnified
party has been authorized in writing by the indemnifying parties, (ii) the indemnified party shall have been advised by counsel
that there may be one or more legal defenses available to it which are different from or in addition to those available to the
indemnifying party (in which case the indemnifying parties shall not have the right to direct the defense of such action on behalf
of the indemnified party) or (iii) the indemnifying parties shall not have employed counsel to assume the defense of such action
within a reasonable time after notice of the commencement thereof, in each of which cases the fees and expenses of counsel shall
be at the expense of the indemnifying parties. An indemnifying party shall not be liable for any settlement of any action, suit,
and proceeding or claim effected without its written consent, which consent shall not be unreasonably withheld or delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6. <U>Contribution</U>.
In order to provide for just and equitable contribution in circumstances in which the indemnification provided for in
Section 5(a) or 5(b) is due in accordance with its terms but for any reason is unavailable to or insufficient to hold
harmless an indemnified party in respect to any losses, liabilities, claims, damages or expenses referred to therein, then
each indemnifying party shall contribute to the aggregate losses, liabilities, claims, damages and expenses (including any
investigation, legal and other expenses reasonably incurred in connection with, and any amount paid in settlement of, any
action, suit or proceeding or any claims asserted, but after deducting any contribution received by any person entitled
hereunder to contribution from any person who may be liable for contribution) incurred by such indemnified party, as
incurred, in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and
the Underwriters on the other hand from the offering of the Shares and the Warrants pursuant to this Agreement or, if such
allocation is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits
referred to above but also the relative fault of the Company on the one hand and the Underwriters on the other hand in
connection with the statements or omissions which resulted in such losses, liabilities, claims, damages or expenses, as well
as any other relevant equitable considerations. The Company and the Underwriters agree that it would not be just and
equitable if contribution pursuant to this Section 6 were determined by pro rata allocation (even if the Underwriters were
treated as one entity for such purpose) or by any other method of allocation which does not take account of the
equitable considerations referred to above. The aggregate amount of losses, liabilities, claims, damages and expenses
incurred by an indemnified party and referred to above shall be deemed to include any legal or other expenses reasonably
incurred by such indemnified party in investigating, preparing or defending against any litigation, or any investigation or
proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue or
alleged untrue statement or omission or alleged omission. Notwithstanding the provisions of this Section 6, no Underwriter
(except as may be provided in the Agreement Among Underwriters) shall be required to contribute any amount in excess of the
underwriting discounts and commissions applicable to the Shares and the Warrants purchased by such Underwriter. No person
guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to
contribution from any person who was not guilty of such fraudulent misrepresentation. For purposes of this Section 6, each
person, if any, who controls an Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the
Exchange Act shall have the same rights to contribution as such Underwriter, and each director of the Company, each officer
of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of
the Section 15 of the Securities Act or Section 20 of the Exchange Act, shall have the same rights to contribution as the
Company. Any party entitled to contribution will, promptly after receipt of notice of commencement of any action, suit or
proceeding against such party in respect of which a claim for contribution may be made against another party or parties under
this Section 6, notify such party or parties from whom contribution may be sought, but the omission so to notify such party
or parties from whom contribution may be sought shall not relieve the party or parties from whom contribution may be sought
from any other obligation it or they may have hereunder or otherwise than under this Section 6. No party shall be liable for
contribution with respect to any action, suit, proceeding or claim settled without its written consent. The
Underwriters&rsquo; obligations to contribute pursuant to this Section 6 are several in proportion to their respective
underwriting commitments and not joint.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<U>Termination</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
This Agreement may be terminated with respect to the Shares and the Warrants to be purchased at the Closing Date by the Representative
by notifying the Company at any time at or before the Closing Date in the absolute discretion of the Representative if: (i) there
has occurred any material adverse change in the securities markets or any event, act or occurrence that has materially disrupted,
or in the opinion of the Representative, will in the future materially disrupt, the securities markets or there shall be such
a material adverse change in general financial, political or economic conditions or the effect of international conditions on
the financial markets in the United States is such as to make it, in the judgment of the Representative, inadvisable or impracticable
to market the Shares and the Warrants or enforce contracts for the sale of the Shares and the Warrants; (ii) there has occurred
any outbreak or material escalation of hostilities or acts of terrorism or other calamity or crisis the effect of which on the
financial markets of the United States is such as to make it, in the judgment of the Representative, inadvisable or impracticable
to market the Shares and the Warrants or enforce contracts for the sale of the Shares and the Warrants; (iii) trading in the Shares
or any securities of the Company has been suspended or materially limited by the Commission or trading generally on the New York
Stock Exchange, Inc., the NYSE American or the Nasdaq Stock Market has been suspended or materially limited, or minimum or maximum
ranges for prices for securities shall have been fixed, or maximum ranges for prices for securities have been required, by any
of said exchanges or by such system or by order of the Commission, FINRA, or any other governmental or regulatory authority; or
(iv) a banking moratorium has been declared by any state or Federal authority; or (v) in the judgment of the Representative, there
has been, since the time of execution of this Agreement or since the respective dates as of which information is given in the
Prospectus, any material adverse change in the assets, properties, condition, financial or otherwise, or in the results of operations,
business affairs or business prospects of the Company and its subsidiaries considered as a whole, whether or not arising in the
ordinary course of business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
If this Agreement is terminated pursuant to any of its provisions, the Company shall not be under any liability to any Underwriter,
and no Underwriter shall be under any liability to the Company, except that (x) if this Agreement is terminated by the Representative
of the Underwriters because of any failure, refusal or inability on the part of the Company to comply with the terms or to fulfill
any of the conditions of this Agreement, the Company will reimburse the Underwriters for all out-of-pocket expenses (including
the reasonable fees and disbursements of their counsel) incurred by them in connection with the proposed purchase and sale of
the Shares and the Warrants or in contemplation of performing their obligations hereunder and (y) no Underwriter who shall have
failed or refused to purchase the Shares and the Warrants agreed to be purchased by it under this Agreement, without some reason
sufficient hereunder to justify cancellation or termination of its obligations under this Agreement, shall be relieved of liability
to the Company or to the other Underwriters for damages occasioned by its failure or refusal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 67.5pt">&nbsp;</P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<U>Substitution of Underwriters</U>. If any Underwriter shall default in its obligation to purchase on the Closing Date the Shares
and Warrants agreed to be purchased hereunder on the Closing Date, the Representative shall have the right, within 36 hours thereafter,
to make arrangements for one or more of the non-defaulting Underwriters, or any other underwriters, to purchase such Shares and
Warrants on the terms contained herein.&nbsp;If, however, the Representative shall not have completed such arrangements within
such 36-hour period, then the Company shall be entitled to a further period of thirty-six hours within which to procure another
party or other parties satisfactory to the Underwriters to purchase such Shares and Warrants on such terms.&nbsp;If, after giving
effect to any arrangements for the purchase of the Shares and Warrants of a defaulting Underwriter or Underwriters by the Representative
and the Company as provided above, the aggregate number of Shares and Warrants which remains unpurchased on the Closing Date does
not exceed one-eleventh of the aggregate number of all the Shares and Warrants that all the Underwriters are obligated to purchase
on such date, then the Company shall have the right to require each non-defaulting Underwriter to purchase the number of Shares
and Warrants which such Underwriter agreed to purchase hereunder at such date and, in addition, to require each non-defaulting
Underwriter to purchase its pro rata share (based on the number of Shares and Warrants which such Underwriter agreed to purchase
hereunder) of the Shares and Warrants of such defaulting Underwriter or Underwriters for which such arrangements have not been
made; but nothing herein shall relieve a defaulting Underwriter from liability for its default.&nbsp;In any such case, either
the Representative or the Company shall have the right to postpone the Closing Date for a period of not more than seven days in
order to effect any necessary changes and arrangements (including any necessary amendments or supplements to the Registration
Statement or Prospectus or any other documents), and the Company agrees to file promptly any amendments to the Registration Statement
or the Prospectus which in the opinion of the Company and the Underwriters and their counsel may thereby be made necessary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 67.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
after giving effect to any arrangements for the purchase of the Shares and Warrants of a defaulting Underwriter or Underwriters
by the Representative and the Company as provided above, the aggregate number of such Shares and Warrants which remains unpurchased
exceeds 10% of the aggregate number of all the Shares and Warrants to be purchased at such date, then this Agreement shall terminate,
without liability on the part of any non-defaulting Underwriter to the Company, and without liability on the part of the Company,
except as provided in Sections&nbsp;4(b), 5, 6 and 7.&nbsp;The provisions of this Section 8 shall not in any way affect the liability
of any defaulting Underwriter to the Company or the nondefaulting Underwriters arising out of such default.&nbsp;The term &ldquo;Underwriter&rdquo;
as used in this Agreement shall include any person substituted under this Section 8 with like effect as if such person had originally
been a party to this Agreement with respect to such Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<U>Miscellaneous</U>. The respective agreements, representations, warranties, indemnities and other statements of the Company
and the several Underwriters, as set forth in this Agreement or made by or on behalf of them pursuant to this Agreement, shall
remain in full force and effect, regardless of any investigation (or any statement as to the results thereof) made by or on behalf
of any Underwriter or the Company or any of their respective officers, directors or controlling persons referred to in Sections
5 and 6 hereof, and shall survive delivery of and payment for the Shares and the Warrants. In addition, the provisions of Sections
4(b), 5, 6 and 7 shall survive the termination or cancellation of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement has been and is made for the benefit of the Underwriters, the Company and their respective successors and assigns, and,
to the extent expressed herein, for the benefit of persons controlling any of the Underwriters, or the Company, and directors
and officers of the Company, and their respective successors and assigns, and no other person shall acquire or have any right
under or by virtue of this Agreement. The term &ldquo;successors and assigns&rdquo; shall not include any purchaser of Shares
and Warrants from any Underwriter merely because of such purchase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
notices and communications hereunder shall be in writing and mailed or delivered or by telephone or telegraph if subsequently
confirmed in writing, (a) if to the Representative, c/o Oppenheimer &amp; Co. Inc., 85 Broad Street, New York, New York 10004
Attention: Equity Capital Markets, with a copy to Oppenheimer &amp; Co. Inc., 85 Broad Street, New York, New York 10004 Attention:
General Counsel, and to Lowenstein Sandler LLP, 1251 Avenue of the Americas, New York, New York 10020, Attention: Steven M. Skolnick
and (b) if to the Company, to its agent for service as such agent&rsquo;s address appears on the cover page of the Registration
Statement with a copy to The Matt Law Firm, PLLC, 125 East Jefferson Street, Syracuse, New York 13202, Attention: Thomas Slusarczyk.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>This
Agreement shall be governed by and construed in accordance with the laws of the State of New York.</B> This Agreement may be signed
in any number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto
were upon the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
confirm that the foregoing correctly sets forth the agreement among us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Very truly yours,</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding: 0; text-indent: 0; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">ACTINIUM PHARMACEUTICALS,
    INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding: 0 0 1.5pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0 0 1.5pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/
    Sandesh Seth</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name: Sandesh Seth</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chairman
    and CEO</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confirmed:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding: 0; text-indent: 0; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">OPPENHEIMER &amp;
    CO. INC.</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding: 0 0 1.5pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/
    Eric Helenek</FONT></TD>
    <TD STYLE="padding: 0 0 1.5pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Eric
    Helenek</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: &#9;Managing
    Director</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acting
severally on behalf of itself and as</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representative
of the several Underwriters</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Named
in Schedule I annexed hereto</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OPPENHEIMER
    &amp; CO. INC.</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding: 0; text-indent: 0; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding: 0 0 1.5pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">/s/ Eric
    Helenek<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0 0 1.5pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name: Eric Helenek</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: &#9;Managing
    Director</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><I>Underwriting Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
I</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-decoration: none; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name</FONT></TD><TD STYLE="text-decoration: none; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-decoration: none; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number
    of <BR>Shares to <BR>&nbsp;Be Purchased</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-decoration: none"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-decoration: none; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-decoration: none; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number
    of Warrants to Be Purchased</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-decoration: none"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Oppenheimer &amp; Co. Inc.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right">17,200,000<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right">14,620,000<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 76%"></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Maxim <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Group LLC</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right">2,150,000</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right">1,827,500</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>JonesTrading Institutional Services LLC</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right">2,150,000</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right">1,827,500</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right">21,500,000<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right">18,275,000<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 29; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Sch I - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
II</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lock-up
Signatories</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark
S. Berger</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
Nicholson</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve
O&rsquo;Loughlin</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nitya
Ray</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh
Seth</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ajit
S. Shetty</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard
Steinhart</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 30; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Sch II - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
III</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pricing
Information (to be provided orally only)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
of Shares to be Issued: 21,500,000 shares</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
of Warrants to be Issued: Warrants to Purchase 18,275,000 shares of Common Stock</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
Coverage: 85%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offering
Price: $0.75 per share and related Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
Exercise Price: $1.05 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting
Discount: 6.0%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Sch
III - 1</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>f8k072817ex5i_actinium.htm
<DESCRIPTION>OPINION OF THE MATT LAW FIRM, PLLC.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 5.1</B></FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex5i.jpg" ALT="">&nbsp;&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
28, 2017</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actinium
Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">275
Madison Avenue, 7th Floor</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York 10016</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
have requested our opinion, as special counsel to Actinium Pharmaceuticals, Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;),
with respect to certain matters in connection with the offering by the Company of up to 21,500,000 shares of its common stock,
par value $0.001 (the &ldquo;<B>Shares</B>&rdquo;), plus warrants (the <B>&ldquo;Warrants&rdquo;</B>) to purchase an additional
18,275,000 shares of the Company&rsquo;s common stock (the <B>&ldquo;Warrant Shares&rdquo;</B>) pursuant to the Registration Statement
on Form S-3 (No. 333-194768) (the &ldquo;<B>Registration Statement</B>&rdquo;) filed with the Securities and Exchange Commission
(the &ldquo;<B>Commission</B>&rdquo;) under the Securities Act of 1933 (the &ldquo;<B>Act</B>&rdquo;), the prospectus included
within the Registration Statement declared effective April&nbsp;17, 2014 (the &ldquo;<B>Base Prospectus</B>&rdquo;), and the prospectus
supplement dated July 28, 2017 filed with the Commission pursuant to Rule 424(b) of the Rules and Regulations of the Act (the
&ldquo;<B>Prospectus Supplement</B>&rdquo;). (The Base Prospectus and Prospectus Supplement are collectively referred to as the
&ldquo;<B>Prospectus</B>.&rdquo;). The Shares, the Warrants and the Warrant Shares are to be sold by the Company as described
in the Registration Statement and the Prospectus.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have examined and relied upon the Registration Statement and the Prospectus, the Company&rsquo;s Certificate of Incorporation
and By-laws, as currently in effect, and the originals or copies certified to our satisfaction of such records, documents, certificates,
memoranda and other instruments as we have deemed relevant in connection with this opinion. We have assumed the genuineness and
authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies,
and the accuracy, completeness and authenticity of certificates of public officials.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are licensed to practice in the State of New York. This opinion letter is limited to New York law, the Delaware General Corporation
Law and applicable federal law of the United States. We are not rendering any opinion as to compliance with any federal or state
antifraud law, rule or regulation relating to securities or to the sale or issuance thereof. With regard to our opinion regarding
the Warrant Shares to be sold upon exercise of the Warrants after the date hereof, we express no opinion to the extent that, notwithstanding
its current reservation of shares of Common Stock, future issuances by the Company of securities, including the Warrant Shares,
and antidilution adjustments to outstanding securities, including the Warrants, may cause the Warrants to be exercisable for more
shares of Common Stock than the number of shares of Common Stock which then are authorized but unissued.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the basis of the foregoing, and in reliance thereon, and subject to the qualifications herein stated, we are of the opinion that
(i) the Shares, when issued and sold in accordance with the Registration Statement and the Prospectus, will be validly issued,
fully paid and nonassessable, (ii) provided that the Warrants have been duly executed and delivered by the Company and duly delivered
to the purchasers thereof against payment therefor, the Warrants, when issued and sold as contemplated in the Registration Statement
and Prospectus, will be valid and legally binding obligations of the Company, enforceable against the Company in accordance with
their terms, except as enforcement thereof may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar
laws relating to or affecting creditors&rsquo; rights generally and by general equitable principles (regardless of whether such
enforceability is considered in a proceeding at law or in equity), and (iii) the Warrant Shares, when issued and paid for in accordance
with the terms of the Warrants, will be validly issued, fully paid and nonassessable.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 1; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">July 28, 2017</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Page 2</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the reference to our firm under the caption &ldquo;Legal Matters&rdquo; in the Prospectus and to the filing of this
opinion as an exhibit to a Current Report on Form 8-K to be filed with the Commission for incorporation by reference into the
Registration Statement. In giving this consent, we do not admit that we are &ldquo;experts&rdquo; within the meaning of Section
11 of the Securities Act or within the category of persons whose consent is required by Section 7 of the Securities Act.&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 11pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Very
truly yours,</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
The Matt Law Firm, PLLC</font></TD></TR>
</TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>f8k072817ex10i_actinium.htm
<DESCRIPTION>FORM OF WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[FORM OF WARRANT]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ACTINIUM
PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Warrant
To Purchase Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Warrant No.: <U>&#9;____________</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Number of Shares of Common Stock:<U>_____________</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date of Issuance: August [ &nbsp;&nbsp;&nbsp;], 2017 (&ldquo;<B>Issuance Date</B>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Actinium Pharmaceuticals,
Inc., a company organized under the laws of Delaware (the &ldquo;<B>Company</B>&rdquo;), hereby certifies that, for good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged<FONT STYLE="text-transform: uppercase">, [HOLDER]</FONT>,
the registered holder hereof or its permitted assigns (the &ldquo;<B>Holder</B>&rdquo;), is entitled, subject to the terms set forth
below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, at any time or times on or after
August [ &nbsp;&nbsp;&nbsp;], 2017 (the &ldquo;<B>Initial Exercisability Date</B>&rdquo;), but not after 11:59 p.m., New York time, on the Expiration
Date, (as defined below), ______________ (_____________)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT>
fully paid non-assessable shares of Common Stock (as defined below), subject to adjustment as provided herein (the &ldquo;<B>Warrant
Shares</B>&rdquo;). Except as otherwise defined herein, capitalized terms in this Warrant to Purchase Common Stock (including any
Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, this &ldquo;<B>Warrant</B>&rdquo;), shall have
the meanings set forth in Section 16. This Warrant is one of the Warrants to purchase Common Stock (the &ldquo;<B>Warrants</B>&rdquo;)
issued pursuant to (i) that certain Underwriting Agreement, dated as of July 28, 2017 (the &ldquo;<B>Subscription Date</B>&rdquo;)
by and between the Company and Oppenheimer &amp; Co. Inc., (ii) the Company&rsquo;s Registration Statement on Form S-3 (File number 333-194768)
(the &ldquo;<B>Registration Statement</B>&rdquo;) and (iii) the Company&rsquo;s prospectus supplement dated as of July 28, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>1
</SUP></FONT>Insert [ &nbsp;&nbsp;&nbsp;&nbsp;]% of the number of shares of Common Stock purchased pursuant to the Underwriting Agreement.</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 1; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">  </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">1.&nbsp;&nbsp;&nbsp;<U>EXERCISE OF WARRANT.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 108pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><U>Mechanics of Exercise</U>. Subject to the terms and conditions hereof (including, without limitation, the limitations
set forth in Section 1(f)), this Warrant may be exercised by the Holder at any time or times on or after the Initial Exercisability
Date, in whole or in part, by delivery (whether via facsimile, electronic mail or otherwise) of a written notice, in the form
attached hereto as <U>Exhibit A</U> (the &ldquo;<B>Exercise Notice</B>&rdquo;), of the Holder&rsquo;s election to exercise this
Warrant. Within two (2) Trading Days following the delivery of the Exercise Notice, the Holder shall make payment to the Company
of an amount equal to the Exercise Price in effect on the date of such exercise multiplied by the number of Warrant Shares as
to which this Warrant is being exercised (the &ldquo;<B>Aggregate Exercise Price</B>&rdquo;) in cash by wire transfer of immediately
available funds or, if the provisions of Section 1(d) are applicable, by notifying the Company that this Warrant is being exercised
pursuant to a Cashless Exercise (as defined in Section 1(d)). The Holder shall not be required to deliver the original Warrant
in order to effect an exercise hereunder, nor shall any ink-original signature or medallion guarantee (or other type of guarantee
or notarization) with respect to any Exercise Notice be required. Execution and delivery of the Exercise Notice with respect to
less than all of the Warrant Shares shall have the same effect as cancellation of the original Warrant and issuance of a new Warrant
evidencing the right to purchase the remaining number of Warrant Shares. On or before the first (1<SUP>st</SUP>) Trading Day following
the date on which the Company has received the applicable Exercise Notice, the Company shall transmit by facsimile or electronic
mail an acknowledgment of confirmation of receipt of the Exercise Notice, in the form attached to the Exercise Notice, to the
Holder and the Company&rsquo;s transfer agent (the &ldquo;<B>Transfer Agent</B>&rdquo;). So long as the Holder delivers the Aggregate
Exercise Price (or notice of a Cashless Exercise) on or prior to the second (2<SUP>nd</SUP>) Trading Day following the date on
which the Exercise Notice has been delivered to the Company, then on or prior to the earlier of (i) the third (3<SUP>rd</SUP>)
Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period, in each case following the date on
which the Exercise Notice has been delivered to the Company, or, if the Holder does not deliver the Aggregate Exercise Price (or
notice of a Cashless Exercise) on or prior to the second (2<SUP>nd</SUP>) Trading Day following the date on which the Exercise
Notice has been delivered to the Company, then on or prior to the first (1st) Trading Day following the date on which the Aggregate
Exercise Price (or notice of a Cashless Exercise) is delivered (such earlier date, the &ldquo;<B>Share Delivery Date</B>&rdquo;),
the Company shall (X) provided that the Transfer Agent is participating in The Depository Trust Company (&ldquo;<B>DTC</B>&rdquo;)
Fast Automated Securities Transfer Program, credit such aggregate number of Warrant Shares to which the Holder is entitled pursuant
to such exercise to the Holder&rsquo;s or its designee&rsquo;s balance account with DTC through its Deposit / Withdrawal At Custodian
system, or (Y) if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program, issue and dispatch
by overnight courier to the address as specified in the Exercise Notice, a certificate, registered in the name of the Holder or
its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise. The Company shall be
responsible for all fees and expenses of the Transfer Agent and all fees and expenses with respect to the issuance of Warrant
Shares via DTC, if any, including without limitation for same day processing. Upon delivery of the Exercise Notice, the Holder
shall be deemed for all corporate purposes to have become the holder of record and beneficial owner of the Warrant Shares with
respect to which this Warrant has been exercised, irrespective of the date such Warrant Shares are credited to the Holder&rsquo;s
DTC account or the date of delivery of the certificates evidencing such Warrant Shares, as the case may be. If this Warrant is
physically delivered to the Company in connection with any exercise pursuant to this Section 1(a) and the number of Warrant Shares
represented by this Warrant submitted for exercise is greater than the number of Warrant Shares being acquired upon an exercise,
then the Company shall as soon as practicable and in no event later than three (3) Trading Days after any exercise and at its
own expense, issue and deliver to the Holder (or its designee) a new Warrant (in accordance with Section 7(d)) representing the
right to purchase the number of Warrant Shares issuable immediately prior to such exercise under this Warrant, less the number
of Warrant Shares with respect to which this Warrant is exercised. No fractional Warrant Shares are to be issued upon the exercise
of this Warrant, but rather the number of Warrant Shares to be issued shall be rounded to the nearest whole number. The Company
shall pay any and all transfer, stamp, issuance and similar taxes, costs and expenses (including, without limitation, fees and
expenses of the Transfer Agent) which may be payable with respect to the issuance and delivery of Warrant Shares upon exercise
of this Warrant. The Company&rsquo;s obligations to issue and deliver Warrant Shares in accordance with the terms and subject
to the conditions hereof are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same,
any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce
the same, or any setoff, counterclaim, recoupment, limitation or termination; <U>provided</U>, <U>however</U>, that the Company
shall not be required to deliver Warrant Shares with respect to an exercise prior to the Holder&rsquo;s delivery of the Aggregate
Exercise Price (or notice of a Cashless Exercise) with respect to such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><U>Exercise
Price</U>. For purposes of this Warrant, &ldquo;<B>Exercise Price</B>&rdquo; means $1.05 per share, subject to adjustment as provided
herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(c)&nbsp;&nbsp;&nbsp;<U>Company&rsquo;s
Failure to Timely Deliver Securities</U>. If either (I) the Company shall fail for any reason or for no reason to issue to
the Holder on or prior to the applicable Share Delivery Date, if (x) the Transfer Agent is not participating in the DTC Fast
Automated Securities Transfer Program, a certificate for the number of shares of Common Stock to which the Holder is entitled
and register such Common Stock on the Company&rsquo;s share register or (y) if the Transfer Agent is participating in the DTC
Fast Automated Securities Transfer Program, to credit the Holder&rsquo;s balance account with DTC, for such number of shares
of Common Stock to which the Holder is entitled upon the Holder&rsquo;s exercise of this Warrant or (II) a registration
statement (which may be the Registration Statement) covering the issuance or resale of the Warrant Shares that are the
subject of the Exercise Notice (the &ldquo;<B>Exercise Notice Warrant Shares</B>&rdquo;) is not available for the issuance or
resale, as applicable, of such Exercise Notice Warrant Shares and (x) the Company fails to promptly, but in no event later
than one (1) Business Day after such registration statement becomes unavailable, to so notify the Holder and (y) the Company
is unable to deliver the Exercise Notice Warrant Shares electronically without any restrictive legend by crediting such
aggregate number of Exercise Notice Warrant Shares to the Holder&rsquo;s or its designee&rsquo;s balance account with DTC
through its Deposit / Withdrawal At Custodian system (the event described in the immediately foregoing clause (II) is
hereinafter referred as a &ldquo;<B>Notice Failure</B>&rdquo; and together with the event described in clause (I) above, an
&ldquo;<B>Exercise Failure</B>&rdquo;), then, in addition to all other remedies available to the Holder, if on or prior to
the applicable Share Delivery Date either (I) if the Transfer Agent is not participating in the DTC Fast Automated Securities
Transfer Program, the Company shall fail to issue and deliver a certificate to the Holder and register such shares of Common
Stock on the Company&rsquo;s share register or, if the Transfer Agent is participating in the DTC Fast Automated Securities
Transfer Program, credit the Holder&rsquo;s balance account with DTC for the number of shares of Common Stock to which the
Holder is entitled upon the Holder&rsquo;s exercise hereunder or pursuant to the Company&rsquo;s obligation pursuant to
clause (ii) below or (II) if a Notice Failure occurs, and if on or after such Trading Day the Holder purchases (in an open
market transaction or otherwise) Common Stock to deliver in satisfaction of a sale by the Holder of shares of Common Stock
issuable upon such exercise that the Holder anticipated receiving from the Company (a &ldquo;<B>Buy-In</B>&rdquo;), then the
Company shall, within three (3) Trading Days after the Holder&rsquo;s request and in the Holder&rsquo;s discretion,
either (i) pay cash to the Holder in an amount equal to the Holder&rsquo;s total purchase price (including brokerage
commissions and other out-of-pocket expenses, if any) for the shares of Common Stock so purchased (the &ldquo;<B>Buy-In
Price</B>&rdquo;), at which point the Company&rsquo;s obligation to deliver such certificate (and to issue such shares of
Common Stock) or credit such Holder&rsquo;s balance account with DTC for such shares of Common Stock shall terminate, or (ii)
promptly honor its obligation to deliver to the Holder a certificate or certificates representing such shares of Common Stock
or credit such Holder&rsquo;s balance account with DTC, as applicable, and pay cash to the Holder in an amount equal to the
excess (if any) of the Buy-In Price over the product of (A) such number of shares of Common Stock, times (B) any trading
price of the Common Stock selected by the Holder in writing as in effect at any time during the period beginning on the
applicable Exercise Date and ending on the applicable Share Delivery Date. Nothing shall limit the Holder&rsquo;s right to
pursue any other remedies available to it hereunder, at law or in equity, including, without limitation, a decree of specific
performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver certificates representing
Warrant Shares (or to electronically deliver such Warrant Shares) upon the exercise of this Warrant as required pursuant to
the terms hereof. While this Warrant is outstanding, the Company shall cause its transfer agent to participate in the DTC
Fast Automated Securities Transfer Program. In addition to the foregoing rights, (i) if the Company fails to deliver the
applicable number of Warrant Shares upon an exercise pursuant to Section 1 by the applicable Share Delivery Date, then the
Holder shall have the right to rescind such exercise in whole or in part and retain and/or have the Company return, as the
case may be, any portion of this Warrant that has not been exercised pursuant to such Exercise Notice; provided that the
rescission of an exercise shall not affect the Company&rsquo;s obligation to make any payments that have accrued prior to the
date of such notice pursuant to this Section 1(c) or otherwise, and (ii) if a registration statement (which may be the
Registration Statement) covering the issuance or resale of the Warrant Shares that are subject to an Exercise Notice is
not available for the issuance or resale, as applicable, of such Exercise Notice Warrant Shares and the Holder has submitted
an Exercise Notice prior to receiving notice of the non-availability of such registration statement and the Company has not
already delivered the Warrant Shares underlying such Exercise Notice electronically without any restrictive legend by
crediting such aggregate number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the
Holder&rsquo;s or its designee&rsquo;s balance account with DTC through its Deposit / Withdrawal At Custodian system, the
Holder shall have the option, by delivery of notice to the Company, to (x) rescind such Exercise Notice in whole or in part
and retain or have returned, as the case may be, any portion of this Warrant that has not been exercised pursuant to such
Exercise Notice; provided that the rescission of an Exercise Notice shall not affect the Company&rsquo;s obligation to make
any payments that have accrued prior to the date of such notice pursuant to this Section 1(c) or otherwise, and/or (y) switch
some or all of such Exercise Notice from a cash exercise to a Cashless Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT><U>Cashless Exercise</U>. Notwithstanding anything contained herein to the contrary, if a registration statement (which
may be the Registration Statement) covering the issuance or resale of the Exercise Notice Warrant Shares is not available for the
issuance or resale, as applicable, of such Exercise Notice Warrant Shares, the Holder may, in its sole discretion, exercise this
Warrant in whole or in part and, in lieu of making the cash payment otherwise contemplated to be made to the Company upon such
exercise in payment of the Aggregate Exercise Price, elect instead to receive upon such exercise the &ldquo;Net Number&rdquo; of
shares of Common Stock determined according to the following formula (a &ldquo;<B>Cashless Exercise</B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify; text-indent: 0pt">Net Number
= <U>(A x B) - (A x C)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; margin-left: 2.75in">B</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify; text-indent: 0pt">For purposes
of the foregoing formula:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify; text-indent: -18pt">A= &nbsp;the total
number of shares with respect to which this Warrant is then being exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify; text-indent: -18pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify; text-indent: -18pt">B= &nbsp;as applicable:
(i) the Closing Sale Price of the Common Stock on the Trading Day immediately preceding the date of the applicable Exercise Notice
if such Exercise Notice is (1) both executed and delivered pursuant to Section 1(a) hereof on a day that is not a Trading Day or
(2) both executed and delivered pursuant to Section 1(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading
hours&rdquo; (as defined in Rule 600(b)(64) of Regulation NMS promulgated under the federal securities laws) on such Trading Day,
(ii) at the option of the Holder, either (y) the Weighted Average Price on the Trading Day immediately preceding the date of the
applicable Notice of Exercise or (z) the Bid Price of the Common Stock as of the time of the Holder&rsquo;s execution of the applicable
Exercise Notice if such Exercise Notice is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered
within two (2) hours thereafter pursuant to Section 1(a) hereof or (iii) the Closing Sale Price of the Common Stock on the date
of the applicable Exercise Notice if the date of such Exercise Notice is a Trading Day and such Exercise Notice is both executed
and delivered pursuant to Section 1(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 90pt; text-align: justify; text-indent: -18pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 94.5pt; text-align: justify; text-indent: -22.5pt">C= &nbsp;the
Exercise Price then in effect for the applicable Warrant Shares at the time of such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 94.5pt; text-align: justify; text-indent: -22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72pt; background-color: white">If
Warrant Shares are issued in such a cashless exercise, the Company acknowledges and agrees that in accordance with Section 3(a)(9)
of the Securities Act of 1933, as amended, the Warrant Shares shall take on the registered characteristics of the Warrants being
exercised, and the holding period of the Warrants being exercised may be tacked on to the holding period of the Warrant Shares.
The Company agrees not to take any position contrary to this Section 1(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><U>Disputes</U>. In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of
the Warrant Shares, the Company shall promptly issue to the Holder the number of Warrant Shares that are not disputed and resolve
such dispute in accordance with Section 11.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><U>Beneficial Ownership</U>. Notwithstanding anything to the contrary contained herein, the Company shall not effect the
exercise of any portion of this Warrant, and the Holder shall not have the right to exercise any portion of this Warrant, pursuant
to the terms and conditions of this Warrant and any such exercise shall be null and void and treated as if never made, to the
extent that after giving effect to such exercise, the Holder together with the other Attribution Parties collectively would beneficially
own in excess of [4.99][9.99]% (the &ldquo;<B>Maximum Percentage</B>&rdquo;) of the number of shares of Common Stock outstanding
immediately after giving effect to such exercise. For purposes of the foregoing sentence, the aggregate number of shares of Common
Stock beneficially owned by the Holder and the other Attribution Parties shall include the number of shares of Common Stock held
by the Holder and all other Attribution Parties plus the number of shares of Common Stock issuable upon exercise of this Warrant
with respect to which the determination of such sentence is being made, but shall exclude the number of shares of Common Stock
which would be issuable upon (A) exercise of the remaining, unexercised portion of this Warrant beneficially owned by the Holder
or any of the other Attribution Parties and (B) exercise or conversion of the unexercised or unconverted portion of any other
securities of the Company (including, without limitation, any convertible notes or convertible preferred stock or warrants, including
the other Warrants) beneficially owned by the Holder or any other Attribution Party subject to a limitation on conversion or exercise
analogous to the limitation contained in this Section 1(f). For purposes of this Section 1(f), beneficial ownership shall be calculated
in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the &ldquo;<B>1934 Act</B>&rdquo;). For purposes
of this Warrant, in determining the number of outstanding shares of Common Stock the Holder may acquire upon the exercise of this
Warrant without exceeding the Maximum Percentage, the Holder may rely on the number of outstanding shares of Common Stock as reflected
in (x) the Company&rsquo;s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and Current Reports on Form 8-K
or other public filing with the Securities and Exchange Commission (the &ldquo;<B>SEC</B>&rdquo;), as the case may be, (y) a more
recent public announcement by the Company or (3) any other written notice by the Company or the Transfer Agent setting forth the
number of shares of Common Stock outstanding (the &ldquo;<B>Reported Outstanding Share Number</B>&rdquo;). If the Company receives
an Exercise Notice from the Holder at a time when the actual number of outstanding shares of Common Stock is less than the Reported
Outstanding Share Number, the Company shall (i) notify the Holder in writing of the number of shares of Common Stock then outstanding
and, to the extent that such Exercise Notice would otherwise cause the Holder&rsquo;s beneficial ownership, as determined pursuant
to this Section 1(f), to exceed the Maximum Percentage, the Holder must notify the Company of a reduced number of Warrant Shares
to be purchased pursuant to such Exercise Notice (the number of shares by which such purchase is reduced, the &ldquo;<B>Reduction
Shares</B>&rdquo;) and (ii) as soon as reasonably practicable, the Company shall return to the Holder any exercise price paid
by the Holder for the Reduction Shares. For any reason at any time, upon the written or oral request of the Holder, the Company
shall within one (1) Business Day confirm orally and in writing or by electronic mail to the Holder the number of shares of Common
Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect
to the conversion or exercise of securities of the Company, including this Warrant, by the Holder and any other Attribution Party
since the date as of which the Reported Outstanding Share Number was reported. In the event that the issuance of Common Stock
to the Holder upon exercise of this Warrant results in the Holder and the other Attribution Parties being deemed to beneficially
own, in the aggregate, more than the Maximum Percentage of the number of outstanding shares of Common Stock (as determined under
Section 13(d) of the 1934 Act), the number of shares so issued by which the Holder&rsquo;s and the other Attribution Parties&rsquo;
aggregate beneficial ownership exceeds the Maximum Percentage (the &ldquo;<B>Excess Shares</B>&rdquo;) shall be deemed null and
void and shall be cancelled ab initio, and the Holder shall not have the power to vote or to transfer the Excess Shares. As soon
as reasonably practicable after the issuance of the Excess Shares has been deemed null and void, the Company shall return to the
Holder the exercise price paid by the Holder for the Excess Shares. Upon delivery of a written notice to the Company, the Holder
may from time to time increase or decrease the Maximum Percentage to any other percentage not in excess of 9.99% as specified
in such notice; provided that (i) any such increase in the Maximum Percentage will not be effective until the sixty-first (61<SUP>st</SUP>)
day after such notice is delivered to the Company and (ii) any such increase or decrease will apply only to the Holder and the
other Attribution Parties and not to any other holder of Warrants that is not an Attribution Party of the Holder. For purposes
of clarity, the shares of Common Stock issuable pursuant to the terms of this Warrant in excess of the Maximum Percentage shall
not be deemed to be beneficially owned by the Holder for any purpose including for purposes of Section 13(d) or Rule 16a-1(a)(1)
of the 1934 Act. No prior inability to exercise this Warrant pursuant to this paragraph shall have any effect on the applicability
of the provisions of this paragraph with respect to any subsequent determination of exercisability. The provisions of this paragraph
shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 1(f) to the
extent necessary to correct this paragraph or any portion of this paragraph which may be defective or inconsistent with the intended
beneficial ownership limitation contained in this Section 1(f) or to make changes or supplements necessary or desirable to properly
give effect to such limitation. The limitation contained in this paragraph may not be waived and shall apply to a successor holder
of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><U>Required Reserve Amount</U>.&nbsp; So long as this Warrant remains outstanding, the Company shall at all times keep reserved
for issuance under this Warrant a number of shares of Common Stock at least equal to 100% of the maximum number of shares of Common
Stock as shall be necessary to satisfy the Company&rsquo;s obligation to issue shares of Common Stock under the Warrants then outstanding
(without regard to any limitations on exercise) (the &ldquo;<B>Required Reserve Amount</B>&rdquo;); <U>provided</U> that at no time
shall the number of shares of Common Stock reserved pursuant to this Section 1(g) be reduced other than in connection with any
exercise of Warrants or such other event covered by Section 2(c) below.&nbsp; The Required Reserve Amount (including, without limitation,
each increase in the number of shares so reserved) shall be allocated pro rata among the holders of the Warrants based on the number
of shares of Common Stock issuable upon exercise of Warrants held by each holder thereof on the Issuance Date (without regard to
any limitations on exercise) (the &ldquo;<B>Authorized Share Allocation</B>&rdquo;). In the event that a holder shall sell or otherwise
transfer any of such holder&rsquo;s Warrants, each transferee shall be allocated a pro rata portion of such holder&rsquo;s Authorized
Share Allocation. Any shares of Common Stock reserved and allocated to any Person which ceases to hold any Warrants shall be allocated
to the remaining holders of Warrants, pro rata based on the number of shares of Common Stock issuable upon exercise of the Warrants
then held by such holders thereof (without regard to any limitations on exercise).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><U>Insufficient Authorized Shares</U>. If at any time while this Warrant remains outstanding the Company does not have a
sufficient number of authorized and unreserved shares of Common Stock to satisfy its obligation to reserve for issuance the Required
Reserve Amount (an &ldquo;<B>Authorized Share Failure</B>&rdquo;), then the Company shall promptly take all action reasonably necessary
to increase the Company&rsquo;s authorized shares of Common Stock to an amount sufficient to allow the Company to reserve the Required
Reserve Amount for this Warrant then outstanding. Without limiting the generality of the foregoing sentence, as soon as practicable
after the date of the occurrence of an Authorized Share Failure, but in no event later than ninety (90) days after the occurrence
of such Authorized Share Failure, the Company shall hold a meeting of its stockholders for the approval of an increase in the number
of authorized shares of Common Stock. In connection with such meeting, the Company shall provide each stockholder with a proxy
statement and shall use its reasonable best efforts to solicit its stockholders&rsquo; approval of such increase in authorized shares
of Common Stock and to cause its board of directors to recommend to the stockholders that they approve such proposal. Notwithstanding
the foregoing, if any such time of an Authorized Share Failure, the Company is able to obtain the written consent of a majority
of the shares of its issued and outstanding shares of Common Stock to approve the increase in the number of authorized shares of
Common Stock, the Company may satisfy this obligation by obtaining such consent and submitting for filing with the SEC an Information
Statement on Schedule 14C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><U>ADJUSTMENT
OF EXERCISE PRICE AND NUMBER OF WARRANT SHARES</U>. The Exercise Price and the number of Warrant Shares shall be adjusted from
time to time as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><U>Voluntary
Adjustment By Company</U>. The Company may at any time during the term of this Warrant reduce the then current Exercise Price
to any amount and for any period of time deemed appropriate by the Board of Directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><U>Adjustment
Upon Subdivision or Combination of Common Stock</U>. If the Company at any time on or after the Subscription Date subdivides (by
any stock split, stock dividend, recapitalization or otherwise) one or more classes of its outstanding shares of Common Stock
into a greater number of shares, the Exercise Price in effect immediately prior to such subdivision will be proportionately reduced
and the number of Warrant Shares will be proportionately increased. If the Company at any time on or after the Subscription Date
combines (by combination, reverse stock split or otherwise) one or more classes of its outstanding shares of Common Stock into
a smaller number of shares, the Exercise Price in effect immediately prior to such combination will be proportionately increased
and the number of Warrant Shares will be proportionately decreased. Any adjustment under this Section&nbsp;2(b) shall become effective
at the close of business on the date the subdivision or combination becomes effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><U>Other Events</U>. If any event occurs of the type contemplated by the provisions of this Section 2 but not expressly
provided for by such provisions (including, without limitation, the granting of stock appreciation rights, phantom stock rights
or other rights with equity features), then the Company&rsquo;s Board of Directors will make an appropriate adjustment in the
Exercise Price and the number of Warrant Shares, as mutually determined by the Company&rsquo;s Board of Directors and the Required
Holders, so as to protect the rights of the Holder; <U>provided</U> that no such adjustment pursuant to this Section 2(c) will
increase the Exercise Price or decrease the number of Warrant Shares as otherwise determined pursuant to this Section 2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><U>RIGHTS
UPON DISTRIBUTION OF ASSETS</U>. In addition to any adjustments pursuant to Section 2 above, if, on or after the Subscription
Date and on or prior to the Expiration Date, the Company shall declare or make any dividend or other distribution of its assets
(or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without
limitation, any distribution of cash, stock or other securities, property, options, evidence of indebtedness or any other assets
by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction)
(a &ldquo;<B>Distribution</B>&rdquo;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall
be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder
had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations
or restrictions on exercise of this Warrant, including without limitation, the Maximum Percentage) immediately before the date
on which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>, that to the
extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder and the other Attribution
Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in such Distribution to such extent
(and shall not be entitled to beneficial ownership of such shares of Common Stock as a result of such Distribution (and beneficial
ownership) to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until
such time or times as its right thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum
Percentage, at which time or times the Holder shall be granted such Distribution (and any Distributions declared or made on such
initial Distribution or on any subsequent Distribution held similarly in abeyance) to the same extent as if there had been no
such limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><U>PURCHASE
RIGHTS; FUNDAMENTAL TRANSACTIONS</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 108pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><U>Purchase
Rights</U>. In addition to any adjustments pursuant to Section 2 above, if at any time on or after the Subscription Date and on
or prior to the Expiration Date the Company grants, issues or sells any Options, Convertible Securities or rights to purchase
stock, warrants, securities or other property pro rata to the record holders of any class of Common Stock (the &ldquo;<B>Purchase
Rights</B>&rdquo;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate
Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon
complete exercise of this Warrant (without regard to any limitations or restrictions on exercise of this Warrant, including without
limitation, the Maximum Percentage) immediately before the date on which a record is taken for the grant, issuance or sale of
such Purchase Rights, or, if no such record is taken, the date as of which the record holders of Common Stock are to be determined
for the grant, issuance or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that to the extent that the Holder&rsquo;s
right to participate in any such Purchase Right would result in the Holder and the other Attribution Parties exceeding the Maximum
Percentage, then the Holder shall not be entitled to participate in such Purchase Right to such extent (and shall not be entitled
to beneficial ownership of such Common Stock as a result of such Purchase Right (and beneficial ownership) to such extent) and
such Purchase Right to such extent shall be held in abeyance for the benefit of the Holder until such time or times as its right
thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, at which time or times
the Holder shall be granted such right (and any Purchase Right granted, issued or sold on such initial Purchase Right or on any
subsequent Purchase Right to be held similarly in abeyance) to the same extent as if there had been no such limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>Fundamental Transaction. The Company shall not enter into or be party to a Fundamental Transaction unless the Successor
Entity assumes in writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section
4(b), including agreements to deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced
by a written instrument substantially similar in form and substance to this Warrant, including, without limitation, which is exercisable
for a corresponding number of shares of capital stock equivalent to the shares of Common Stock acquirable and receivable upon
exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction,
and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account
the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital
stock, such adjustments to the number of shares of capital stock and such exercise price being for the purpose of protecting the
economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction). Upon the consummation of
each Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for the Company (so that from and after
the date of the applicable Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring
to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and power of the Company
and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had
been named as the Company herein. Upon consummation of each Fundamental Transaction, the Successor Entity shall deliver to the
Holder confirmation that there shall be issued upon exercise of this Warrant at any time after the consummation of the applicable
Fundamental Transaction, in lieu of the shares of Common Stock (or other securities, cash, assets or other property (except such
items still issuable under Sections 3 and 4(a) above, which shall continue to be receivable thereafter)) issuable upon the exercise
of this Warrant prior to the applicable Fundamental Transaction, such shares of common stock (or its equivalent) of the Successor
Entity (including its Parent Entity) which the Holder would have been entitled to receive upon the happening of the applicable
Fundamental Transaction had this Warrant been exercised immediately prior to the applicable Fundamental Transaction (without regard
to any limitations on the exercise of this Warrant), as adjusted in accordance with the provisions of this Warrant. Notwithstanding
the foregoing, and without limiting Section 1(f) hereof, the Holder may elect, at its sole option, by delivery of written notice
to the Company to waive this Section 4(b) to permit the Fundamental Transaction without the assumption of this Warrant. In addition
to and not in substitution for any other rights hereunder, prior to the consummation of each Fundamental Transaction pursuant
to which holders of shares of Common Stock are entitled to receive securities or other assets with respect to or in exchange for
shares of Common Stock (a &ldquo;<B>Corporate Event</B>&rdquo;), the Company shall make appropriate provision to insure that the
Holder will thereafter have the right to receive upon an exercise of this Warrant at any time after the consummation of the applicable
Fundamental Transaction but prior to the Expiration Date, in lieu of the shares of the Common Stock (or other securities, cash,
assets or other property (except such items still issuable under Sections 3 and 4(a) above, which shall continue to be receivable
thereafter)) issuable upon the exercise of the Warrant prior to such Fundamental Transaction , such shares of stock, securities,
cash, assets or any other property whatsoever (including warrants or other purchase or subscription rights) (collectively, the
&ldquo;<B>Corporate Event Consideration</B>&rdquo;) which the Holder would have been entitled to receive upon the happening closing
of the applicable Fundamental Transaction had this Warrant been exercised immediately prior to the applicable Fundamental Transaction
(without regard to any limitations on the exercise of this Warrant). The provision made pursuant to the preceding sentence shall
be in a form and substance reasonably satisfactory to the Holder. Notwithstanding the foregoing, in the event of a Change in Control,
at the request of the Holder delivered before the 30th day after such Change in Control, the Company (or the Successor Entity)
shall purchase this Warrant from the Holder by paying to the Holder, within five (5) Business Days after such request (or, if
later, on the effective date of the Change in Control), an amount equal to the Black Scholes Value of the remaining unexercised
portion of this Warrant on the effective date of such Change of Control, payable in cash, <U>provided</U>, <U>however</U>, that,
solely in the event that the Change in Control is not within the Company&rsquo;s control, including not approved by the Company&rsquo;s
Board of Directors, the Black Scholes Value may be payable in the same type or form of consideration (and in the same proportion)
that is being offered and paid to the holders of Common Stock of the Company in connection with the Change in Control, whether
that consideration be in the form of cash, stock, assets, property or any combination thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><U>NONCIRCUMVENTION</U>.
The Company hereby covenants and agrees that the Company will not, by amendment of its Certificate of Incorporation or Bylaws,
or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issuance or sale
of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, and will at all times in good faith carry out all of the provisions of this Warrant and take all action as may be required
to protect the rights of the Holder. Without limiting the generality of the foregoing, the Company (i)&nbsp;shall not increase
the par value of any shares of Common Stock receivable upon the exercise of this Warrant above the Exercise Price then in effect,
(ii)&nbsp;shall take all such actions as may be necessary or appropriate in order that the Company may validly and legally issue
fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant, and (iii) shall, so long as any of the
Warrants are outstanding, take all action necessary to reserve and keep available out of its authorized and unissued shares of
Common Stock, solely for the purpose of effecting the exercise of the Warrants, the number of shares of Common Stock as shall
from time to time be necessary to effect the exercise of the Warrants then outstanding (without regard to any limitations on exercise).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><U>WARRANT
HOLDER NOT DEEMED A STOCKHOLDER</U>. Except as otherwise specifically provided herein, the Holder, solely in such Person&rsquo;s
capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of capital stock
of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in
such Person&rsquo;s capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to
vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock,
consolidation, merger, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise,
prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise
of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to
purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities
are asserted by the Company or by creditors of the Company. Notwithstanding this Section 6, the Company shall provide the Holder
with copies of the same notices and other information given to the stockholders of the Company generally, contemporaneously with
the giving thereof to the stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><U>REISSUANCE
OF WARRANTS</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 108pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><U>Transfer of Warrant</U>. If this Warrant is to be transferred, the Holder shall surrender this Warrant to the Company,
whereupon the Company will forthwith issue and deliver upon the order of the Holder a new Warrant (in accordance with Section 7(d)),
registered as the Holder may request, representing the right to purchase the number of Warrant Shares being transferred by the
Holder and, if less than the total number of Warrant Shares then underlying this Warrant is being transferred, a new Warrant (in
accordance with Section 7(d)) to the Holder representing the right to purchase the number of Warrant Shares not being transferred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(b)&nbsp;&nbsp;&nbsp;<U>Lost, Stolen
or Mutilated Warrant</U>. Upon receipt by the Company of evidence reasonably satisfactory to the Company of the loss, theft, destruction
or mutilation of this Warrant, and, in the case of loss, theft or destruction, of any indemnification undertaking by the Holder
to the Company in customary form (but without the obligation to post a bond) and, in the case of mutilation, upon surrender and
cancellation of this Warrant, the Company shall execute and deliver to the Holder a new Warrant (in accordance with Section 7(d))
representing the right to purchase the Warrant Shares then underlying this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Exchangeable for Multiple Warrants</U>. This Warrant is exchangeable, upon the surrender hereof by the Holder at the
principal office of the Company, for a new Warrant or Warrants (in accordance with Section 7(d)) representing in the aggregate
the right to purchase the number of Warrant Shares then underlying this Warrant, and each such new Warrant will represent the right
to purchase such portion of such Warrant Shares as is designated by the Holder at the time of such surrender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><U>Issuance of New Warrants</U>. Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant,
such new Warrant (i) shall be of like tenor with this Warrant, (ii) shall represent, as indicated on the face of such new Warrant,
the right to purchase the Warrant Shares then underlying this Warrant (or in the case of a new Warrant being issued pursuant to
Section 7(a) or Section 7(c), the Warrant Shares designated by the Holder which, when added to the number of shares of Common Stock
underlying the other new Warrants issued in connection with such issuance, does not exceed the number of Warrant Shares then underlying
this Warrant), (iii) shall have an issuance date, as indicated on the face of such new Warrant which is the same as the Issuance
Date, and (iv) shall have the same rights and conditions as this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: justify">8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><U>NOTICES</U>.
Whenever notice is required to be given under this Warrant, unless otherwise provided herein, such notice shall be given in writing,
(i) if delivered (a) from within the domestic United States, by first-class registered or certified airmail, or nationally recognized
overnight express courier, postage prepaid, electronic mail or by facsimile or (b) from outside the United States, by International
Federal Express, electronic mail or facsimile, and (ii) will be deemed given (A) if delivered by first-class registered or certified
mail domestic, three (3) Business Days after so mailed, (B) if delivered by nationally recognized overnight carrier, one (1) Business
Day after so mailed, (C) if delivered by International Federal Express, two (2) Business Days after so mailed and (D) on the date
of transmission, if delivered by electronic mail to each of the email addresses specified in this Section 8 prior to 5:00 p.m.
(New York time) on a Trading Day, (E) the next Trading Day after the date of transmission, if delivered by electronic mail to
each of the email addresses specified in this Section 8 on a day that is not a Trading Day or later than 5:00 p.m. (New York time)
on any Trading Day and (E) if delivered by facsimile, upon electronic confirmation of receipt of such facsimile, and will be delivered
and addressed as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">(i)&nbsp;&nbsp;if to
the Company, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">Actinium Pharmaceuticals, Inc.<BR>
275 Madison Avenue, 7<SUP>th</SUP> Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">New York, NY 10016<BR>
Attention: [ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">Facsimile: [ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">Email: [ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: 0pt">(ii) if to the
Holder, at such address or other contact information delivered by the Holder to Company or as is on the books and records of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt">The Company shall provide
the Holder with prompt written notice of all actions taken pursuant to this Warrant, including in reasonable detail a description
of such action and the reason therefor. Without limiting the generality of the foregoing, the Company will give written notice
to the Holder (i) immediately upon any adjustment of the Exercise Price, setting forth in reasonable detail, and certifying, the
calculation of such adjustment and (ii) at least fifteen (15) days prior to the date on which the Company closes its books or takes
a record (A) with respect to any dividend or distribution upon the shares of Common Stock, (B) with respect to any grants, issuances
or sales of any Options, Convertible Securities or rights to purchase stock, warrants, securities or other property to holders
of shares of Common Stock or (C) for determining rights to vote with respect to any Fundamental Transaction, dissolution or liquidation;
<U>provided</U> in each case that such information shall be made known to the public prior to or in conjunction with such notice
being provided to the Holder. It is expressly understood and agreed that the time of exercise specified by the Holder in each Exercise
Notice shall be definitive and may not be disputed or challenged by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: justify">9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><U>AMENDMENT
AND WAIVER</U>. Except as otherwise provided herein, the provisions of this Warrant may be amended or waived and the Company may
take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained
the written consent of the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: justify">10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><U>GOVERNING
LAW; JURISDICTION; JURY TRIAL</U>. This Warrant shall be governed by and construed and enforced in accordance with, and all questions
concerning the construction, validity, interpretation and performance of this Warrant shall be governed by, the internal laws
of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State
of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State
of New York. The Company hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The
City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with any transaction
contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding,
any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought
in an inconvenient forum or that the venue of such suit, action or proceeding is improper. The Company hereby irrevocably waives
personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof
to the Company at the address set forth in Section 8(i) above or such other address as the Company subsequently delivers to the
Holder and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained
herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein
shall be deemed or operate to preclude the Holder from bringing suit or taking other legal action against the Company in any other
jurisdiction to collect on the Company&rsquo;s obligations to the Holder, to realize on any collateral or any other security for
such obligations, or to enforce a judgment or other court ruling in favor of the Holder. <B>THE COMPANY HEREBY IRREVOCABLY WAIVES
ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION
WITH OR ARISING OUT OF THIS WARRANT OR ANY TRANSACTION CONTEMPLATED HEREBY.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: justify">11.&nbsp;&nbsp;&nbsp;<U>DISPUTE RESOLUTION</U>.
In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares, the
Company shall submit the disputed determinations or arithmetic calculations via facsimile or electronic mail within two (2) Business
Days of receipt of the Exercise Notice or other event giving rise to such dispute, as the case may be, to the Holder. If the Holder
and the Company are unable to agree upon such determination or calculation of the Exercise Price or the Warrant Shares within
three (3) Business Days of such disputed determination or arithmetic calculation being submitted to the Holder, then the Company
shall, within two (2) Business Days submit via facsimile or electronic mail (a) the disputed determination of the Exercise Price
to an independent, reputable investment bank selected by the Company and approved by the Holder or (b) the disputed arithmetic
calculation of the Warrant Shares to the Company&rsquo;s independent, outside accountant. The Company shall cause at its expense
the investment bank or the accountant, as the case may be, to perform the determinations or calculations and notify the Company
and the Holder of the results no later than ten (10) Business Days from the time it receives the disputed determinations or calculations.
Such investment bank&rsquo;s or accountant&rsquo;s determination or calculation, as the case may be, shall be binding upon all
parties absent demonstrable error.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: justify">12.&nbsp;&nbsp;&nbsp;<U>REMEDIES,
OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF</U>. The remedies provided in this Warrant shall be cumulative and in addition
to all other remedies available under this Warrant and any other Transaction Documents, at law or in equity (including a decree
of specific performance and/or other injunctive relief), and nothing herein shall limit the right of the Holder to pursue actual
damages for any failure by the Company to comply with the terms of this Warrant. The Company acknowledges that a breach by it
of its obligations hereunder will cause irreparable harm to the Holder and that the remedy at law for any such breach may be inadequate.
The Company therefore agrees that, in the event of any such breach or threatened breach, the holder of this Warrant shall be entitled,
in addition to all other available remedies, to an injunction restraining any breach, without the necessity of showing economic
loss and without any bond or other security being required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: justify">13.&nbsp;<U>TRANSFER</U>.
This Warrant and the Warrant Shares may be offered for sale, sold, transferred, pledged or assigned without the consent of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: justify">14.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><U>SEVERABILITY;
CONSTRUCTION; HEADINGS</U>. If any provision of this Warrant is prohibited by law or otherwise determined to be invalid or unenforceable
by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed
amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such
provision shall not affect the validity of the remaining provisions of this Warrant so long as this Warrant as so modified continues
to express, without material change, the original intentions of the parties as to the subject matter hereof and the prohibited
nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations
or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred upon the
parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s)
with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable
provision(s). This Warrant shall be deemed to be jointly drafted by the Company and the Holder and shall not be construed against
any Person as the drafter hereof. The headings of this Warrant are for convenience of reference and shall not form part of, or
affect the interpretation of, this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: justify">15.&nbsp;<U>DISCLOSURE</U>.
Upon receipt or delivery by the Company of any notice in accordance with the terms of this Warrant, unless the Company has in
good faith determined that the matters relating to such notice do not constitute material, nonpublic information relating to the
Company or its subsidiaries, the Company shall contemporaneously with any such receipt or delivery publicly disclose such material,
nonpublic information on a Current Report on Form 8-K or otherwise. In the event that the Company believes that a notice contains
material, nonpublic information relating to the Company or its subsidiaries, the Company so shall indicate to such Holder contemporaneously
with delivery of such notice, and in the absence of any such indication, the Holder shall be allowed to presume that all matters
relating to such notice do not constitute material, nonpublic information relating to the Company or its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: justify">16.&nbsp;<U>CERTAIN
DEFINITIONS</U>. For purposes of this Warrant, the following terms shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<B>Affiliate</B>&rdquo; means, with respect to any Person, any other Person that directly or indirectly controls,
is controlled by, or is under common control with, such Person, it being understood for purposes of this definition that &ldquo;control&rdquo;
of a Person means the power directly or indirectly either to vote 10% or more of the stock having ordinary voting power for the
election of directors of such Person or direct or cause the direction of the management and policies of such Person whether by
contract or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<B>Attribution Parties</B>&rdquo; means, collectively, the following Persons and entities: (i) any investment vehicle,
including, any funds, feeder funds or managed accounts, currently, or from time to time after the Subscription Date, directly
or indirectly managed or advised by the Holder&rsquo;s investment manager or any of its Affiliates or principals, (ii) any direct
or indirect Affiliates of the Holder or any of the foregoing, (iii) any Person acting or who could be deemed to be acting as a
Group together with the Holder or any of the foregoing and (iv) any other Persons whose beneficial ownership of the Company&rsquo;s
Common Stock would or could be aggregated with the Holder&rsquo;s and the other Attribution Parties for purposes of Section 13(d)
of the 1934 Act. For clarity, the purpose of the foregoing is to subject collectively the Holder and all other Attribution Parties
to the Maximum Percentage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT> &ldquo;<B>Bid Price</B>&rdquo; means, for any security as of the particular time of determination, the bid price for such
security on the Principal Market as reported by Bloomberg as of such time of determination, or, if the Principal Market is not
the principal securities exchange or trading market for such security, the bid price of such security on the principal securities
exchange or trading market where such security is listed or traded as reported by Bloomberg as of such time of determination,
or if the foregoing does not apply, the bid price of such security in the over-the-counter market on the electronic bulletin board
for such security as reported by Bloomberg as of such time of determination, or, if no bid price is reported for such security
by Bloomberg as of such time of determination, the average of the bid prices of any market makers for such security as reported
in the &ldquo;pink sheets&rdquo; by OTC Markets Group Inc. (formerly Pink Sheets LLC) as of such time of determination. If the
Bid Price cannot be calculated for a security as of the particular time of determination on any of the foregoing bases, the Bid
Price of such security as of such time of determination shall be the fair market value as mutually determined by the Company and
the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then such dispute shall
be resolved in accordance with the procedures in Section&nbsp;11. All such determinations shall be appropriately adjusted for
any stock dividend, stock split, stock combination or other similar transaction during such period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<B>Black Scholes Value</B>&rdquo; means the value of this Warrant based on the Black-Scholes Option Pricing Model
obtained from the &ldquo;OV&rdquo; function on Bloomberg determined as of the day immediately following the first public announcement
of the applicable Fundamental Transaction, or, if the Fundamental Transaction is not publicly announced, the date the Fundamental
Transaction is consummated, for pricing purposes and reflecting (i) a risk-free interest rate corresponding to the U.S. Treasury
rate for a period equal to the remaining term of this Warrant as of such date of request, (ii) an expected volatility equal to
the greater of 100% and the 100-day volatility obtained from the HVT function on Bloomberg as of the day immediately following
the public announcement of the applicable Fundamental Transaction, or, if the Fundamental Transaction is not publicly announced,
the date the Fundamental Transaction is consummated, (iii) the underlying price per share used in such calculation shall be the
highest Weighted Average Price during the five (5) Trading Days prior to the closing of the Fundamental Transaction, (iv) a zero
cost of borrow and (v) a 360 day annualization factor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Bloomberg</B>&rdquo; means Bloomberg Financial Markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<B>Business
Day</B>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<B>Change
of Control</B>&rdquo; means any Fundamental Transaction other than (i) any reorganization, recapitalization or reclassification
of the Common Stock in which holders of the Company&rsquo;s majority voting power immediately prior to such reorganization, recapitalization
or reclassification continue after such reorganization, recapitalization or reclassification to hold publicly traded securities
and, directly or indirectly, are, in all material respect, the holders of the majority voting power of the surviving entity (or
entities with the authority or voting power to elect the members of the board of directors (or their equivalent if other than
a corporation) of such entity or entities) after such reorganization, recapitalization or reclassification, (ii) pursuant to a
migratory merger effected solely for the purpose of changing the jurisdiction of incorporation of the Company or (iii) a merger
in connection with a bona fide acquisition by the Company of any Person in which (x) the gross consideration paid, directly or
indirectly, by the Company in such acquisition is not greater than 20% of the Company&rsquo;s market capitalization as calculated
on the date of the consummation of such merger and (y) such merger does not contemplate a change to the identity of a majority
of the board of directors of the Company. Notwithstanding anything herein to the contrary, any transaction or series of transaction
that, directly or indirectly, results in the Company or the Successor Entity not having Common Stock or common stock, as applicable,
registered under the 1934 Act and listed on an Eligible Market shall be deemed a Change of Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>&ldquo;<B>Closing Bid Price</B>&rdquo; and &ldquo;<B>Closing Sale Price</B>&rdquo; means, for any security as of any date,
the last closing bid price and last closing trade price, respectively, for such security on the Principal Market, as reported
by Bloomberg, or, if the Principal Market begins to operate on an extended hours basis and does not designate the closing bid
price or the closing trade price, as the case may be, then the last bid price or the last trade price, respectively, of such security
prior to 4:00:00 p.m., New York time, as reported by Bloomberg, or, if the Principal Market is not the principal securities exchange
or trading market for such security, the last closing bid price or last trade price, respectively, of such security on the principal
securities exchange or trading market where such security is listed or traded as reported by Bloomberg, or if the foregoing do
not apply, the last closing bid price or last trade price, respectively, of such security in the over-the-counter market on the
electronic bulletin board for such security as reported by Bloomberg, or, if no closing bid price or last trade price, respectively,
is reported for such security by Bloomberg, the average of the bid prices, or the ask prices, respectively, of any market makers
for such security as reported in the OTC Link or &ldquo;pink sheets&rdquo; by OTC Markets Group Inc. (formerly Pink OTC Markets
Inc.). If the Closing Bid Price or the Closing Sale Price cannot be calculated for a security on a particular date on any of the
foregoing bases, the Closing Bid Price or the Closing Sale Price, as the case may be, of such security on such date shall be the
fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon
the fair market value of such security, then such dispute shall be resolved pursuant to Section 11. All such determinations to
be appropriately adjusted for any stock dividend, stock split, stock combination, reclassification or other similar transaction
during the applicable calculation period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<B>Common Stock</B>&rdquo; means (i)&nbsp;the Company&rsquo;s Common Stock, par value $0.001 per share, and (ii)&nbsp;any
capital stock into which such Common Stock shall have been changed or any capital stock resulting from a reclassification of such
Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Convertible
Securities</B>&rdquo; means any stock or securities (other than Options) directly or indirectly convertible into or exercisable
or exchangeable for shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
&nbsp; </FONT>&ldquo;<B>Eligible Market</B>&rdquo; means The NASDAQ Capital Market, the NYSE American, The NASDAQ Global Select
Market, The NASDAQ Global Market or The New York Stock Exchange, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Expiration
Date</B>&rdquo; means the date sixty (60) months after the Initial Exercisability Date or, if such date falls on a day other than
a Business Day or on which trading does not take place on the Principal Market (a &ldquo;<B>Holiday</B>&ldquo;), the next day
that is not a Holiday.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(m)&nbsp;&nbsp;&nbsp;&ldquo;<B>Fundamental Transaction</B>&rdquo; means (A) that the Company shall, directly or indirectly,
including through subsidiaries, Affiliates or otherwise, in one or more related transactions, (i) consolidate or merge with or
into (whether or not the Company is the surviving corporation) another Subject Entity, or (ii) sell, assign, transfer, convey
or otherwise dispose of all or substantially all of the properties or assets of the Company or any of its &ldquo;significant subsidiaries&rdquo;
(as defined in Rule 1-02 of Regulation S-X) to one or more Subject Entities, or (iii) make, or allow one or more Subject Entities
to make, or allow the Company to be subject to or have its shares of Common Stock be subject to or party to one or more Subject
Entities making, a purchase, tender or exchange offer that is accepted by the holders of at least either (x) 50% of the outstanding
shares of Common Stock, (y) 50% of the outstanding shares of Common Stock calculated as if any shares of Common Stock held by
all Subject Entities making or party to, or Affiliated with any Subject Entities making or party to, such purchase, tender or
exchange offer were not outstanding; or (z) such number of shares of Common Stock such that all Subject Entities making or party
to, or Affiliated with any Subject Entity making or party to, such purchase, tender or exchange offer, become collectively the
beneficial owners (as defined in Rule 13d-3 under the 1934 Act) of at least 50% of the outstanding shares of Common Stock, or
(iv) consummate a stock purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization,
spin-off or scheme of arrangement) with one or more Subject Entities whereby all such Subject Entities, individually or in the
aggregate, acquire, either (x) at least 50% of the outstanding shares of Common Stock, (y) at least 50% of the outstanding shares
of Common Stock calculated as if any shares of Common Stock held by all the Subject Entities making or party to, or Affiliated
with any Subject Entity making or party to, such stock purchase agreement or other business combination were not outstanding;
or (z) such number of shares of Common Stock such that the Subject Entities become collectively the beneficial owners (as defined
in Rule 13d-3 under the 1934 Act) of at least 50% of the outstanding shares of Common Stock, or (v) reorganize, recapitalize or
reclassify its shares of Common Stock, (B) that the Company shall, directly or indirectly, including through subsidiaries, Affiliates
or otherwise, in one or more related transactions, allow any Subject Entity individually or the Subject Entities in the aggregate
to be or become the &ldquo;beneficial owner&rdquo; (as defined in Rule 13d-3 under the 1934 Act), directly or indirectly, whether
through acquisition, purchase, assignment, conveyance, tender, tender offer, exchange, reduction in outstanding shares of Common
Stock, merger, consolidation, business combination, reorganization, recapitalization, spin-off, scheme of arrangement, reorganization,
recapitalization or reclassification or otherwise in any manner whatsoever, of either (x) at least 50% of the aggregate ordinary
voting power represented by issued and outstanding shares of Common Stock, (y) at least 50% of the aggregate ordinary voting power
represented by issued and outstanding shares of Common Stock not held by all such Subject Entities as of the Subscription Date
calculated as if any shares of Common Stock held by all such Subject Entities were not outstanding, or (z) a percentage of the
aggregate ordinary voting power represented by issued and outstanding shares of Common Stock or other equity securities of the
Company sufficient to allow such Subject Entities to effect a statutory short form merger or other transaction requiring other
stockholders of the Company to surrender their Common Stock without approval of the stockholders of the Company or (C) directly
or indirectly, including through subsidiaries, Affiliates or otherwise, in one or more related transactions, the issuance of or
the entering into any other instrument or transaction structured in a manner to circumvent, or that circumvents, the intent of
this definition in which case this definition shall be construed and implemented in a manner otherwise than in strict conformity
with the terms of this definition to the extent necessary to correct this definition or any portion of this definition which may
be defective or inconsistent with the intended treatment of such instrument or transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<B>Group</B>&rdquo;
means a &ldquo;group&rdquo; as that term is used in Section 13(d) of the 1934 Act and as defined in Rule 13d-5 thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(o)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<B>Options</B>&rdquo;
means any rights, warrants or options to subscribe for or purchase shares of Common Stock or Convertible Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(p)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<B>Parent
Entity</B>&rdquo; of a Person means an entity that, directly or indirectly, controls the applicable Person, including such entity
whose common stock or equivalent equity security is quoted or listed on an Eligible Market (or, if so elected by the Holder, any
other market, exchange or quotation system), or, if there is more than one such Person or such entity, the Person or such entity
designated by the Holder or in the absence of such designation, such Person or entity with the largest public market capitalization
as of the date of consummation of the Fundamental Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(q)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<B>Person</B>&rdquo;
means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization,
any other entity and a government or any department or agency thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(r)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<B>Principal
Market</B>&rdquo; means the NYSE American.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(s)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<B>Required
Holders</B>&rdquo; means the holders of the Warrants representing at least a majority of the shares of Common Stock underlying
the Warrants then outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(t)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<B>Standard
Settlement Period</B>&rdquo; means the standard settlement period, expressed in a number of Trading Days, for the Company&rsquo;s
primary trading market or quotation system with respect to the Common Stock that is in effect on the date of receipt of an applicable
Conversion Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(u)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<B>Subject
Entity</B>&rdquo; means any Person, Persons or Group or any Affiliate or associate of any such Person, Persons or Group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<B>Successor
Entity</B>&rdquo; means one or more Person or Persons (or, if so elected by the Holder, the Company or Parent Entity) formed by,
resulting from or surviving any Fundamental Transaction or one or more Person or Persons (or, if so elected by the Holder, the
Company or the Parent Entity) with which such Fundamental Transaction shall have been entered into.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(w)&nbsp;&nbsp;&nbsp;&ldquo;<B>Trading
Day</B>&rdquo; means any day on which the Common Stock is traded on the Principal Market, or, if the Principal Market is not the
principal trading market for the Common Stock, then on the principal securities exchange or securities market on which the Common
Stock is then traded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<B>Transaction
Documents</B>&rdquo; means any agreement entered into by and between the Company and the Holder, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">(y)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<B>Weighted
Average Price</B>&rdquo; means, for any security as of any date, the dollar volume-weighted average price for such security on
the Principal Market during the period beginning at 9:30:01 a.m., New York time (or such other time as the Principal Market publicly
announces is the official open of trading), and ending at 4:00:00 p.m., New York time (or such other time as the Principal Market
publicly announces is the official close of trading), as reported by Bloomberg through its &ldquo;Volume at Price&rdquo; function
or, if the foregoing does not apply, the dollar volume-weighted average price of such security in the over-the-counter market
on the electronic bulletin board for such security during the period beginning at 9:30:01 a.m., New York time (or such other time
as such market publicly announces is the official open of trading), and ending at 4:00:00 p.m., New York time (or such other time
as such market publicly announces is the official close of trading), as reported by Bloomberg, or, if no dollar volume-weighted
average price is reported for such security by Bloomberg for such hours, the average of the highest Closing Bid Price and the
lowest closing ask price of any of the market makers for such security as reported in the OTC Link or &ldquo;pink sheets&rdquo;
by OTC Markets Group Inc. (formerly Pink OTC Markets Inc.). If the Weighted Average Price cannot be calculated for a security
on a particular date on any of the foregoing bases, the Weighted Average Price of such security on such date shall be the fair
market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the
fair market value of such security, then such dispute shall be resolved pursuant to Section 11 with the term &ldquo;Weighted Average
Price&rdquo; being substituted for the term &ldquo;Exercise Price.&rdquo; All such determinations shall be appropriately adjusted
for any stock dividend, stock split, stock combination, reclassification or other similar transaction during the applicable calculation
period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[Signature Page Follows]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 36pt"><B>IN WITNESS WHEREOF,</B> the Company
has caused this Warrant to Purchase Common Stock to be duly executed as of the Issuance Date set out above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><B>ACTINIUM PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 4%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 36%; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0 0 1.5pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">By:</TD>
    <TD STYLE="padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">Name:</TD>
    <TD STYLE="padding: 0; text-indent: 0"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Title:</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>EXHIBIT
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>EXERCISE
NOTICE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>TO
BE EXECUTED BY THE REGISTERED HOLDER TO EXERCISE THIS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>WARRANT
TO PURCHASE COMMON STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><B>ACTINIUM
PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
undersigned holder hereby exercises the right to purchase _________________ of the shares of Common Stock (&quot;<B>Warrant Shares</B>&quot;)
of Actinium Pharmaceuticals, Inc., a company organized under the laws of Delaware (the &quot;<B>Company</B>&quot;), evidenced
by the attached Warrant to Purchase Common Stock (the &quot;<B>Warrant</B>&quot;). Capitalized terms used herein and not otherwise
defined shall have the respective meanings set forth in the Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.
Form of Exercise Price. The Holder intends that payment of the Exercise Price shall be made as:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">____________&#9;a
&quot;<U>Cash Exercise&quot;</U> with respect to _________________ Warrant Shares; and/or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">____________&#9;a
<U>&quot;Cashless Exercise&quot;</U> with respect to _______________ Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.
Payment of Exercise Price. In the event that the holder has elected a Cash Exercise with respect to some or all of the Warrant
Shares to be issued pursuant hereto, the holder shall pay the Aggregate Exercise Price in the sum of $___________________ to the
Company in accordance with the terms of the Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.
Delivery of Warrant Shares. The Company shall deliver to the holder __________ Warrant Shares in accordance with the terms of
the Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:
_______________ __, ______</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 40%">&nbsp;&nbsp;&nbsp;Name
of Registered Holder</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="width: 31%">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">  A-1</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ACKNOWLEDGMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company hereby acknowledges this Exercise Notice and hereby directs Action Stock Transfer Corporation to issue the above indicated
number of shares of Common Stock on or prior to the applicable Share Delivery Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ACTINIUM PHARMACEUTICALS, INC.</B></FONT></P>

</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding: 0; text-indent: 0; width: 60%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 5%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 35%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">By:</TD>
    <TD STYLE="padding: 0; text-indent: 0; border-bottom: Black 1.5pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT>A-2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>f8k072817ex99i_actinium.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY ACTINIUM PHARMACEUTICALS, INC. DATED JULY 27, 2017
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="ex99i_001.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">Actinium
Announces Proposed Public Offering of Common Stock and Warrants to Purchase Stock</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>New
York, NY &ndash; July 27, 2017</B> &ndash; Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (&ldquo;Actinium&rdquo; or &ldquo;the
Company&rdquo;), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options,
announced today that it intends to offer and sell shares of its common stock and warrants to purchase shares of its common stock
in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to
whether or when the offering may be completed, or as to the actual size or terms of the offering. The Company intends to use the
net proceeds from the proposed offering to fund clinical development of Iomab-B, Actimab-A, Actimab-M, its alpha particle technology
platform, and for general corporate purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oppenheimer
&amp; Co. Inc. is acting as sole book-running manager for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
offering is being conducted pursuant to a shelf registration statement that was previously filed with, and declared effective
by the U.S. Securities and Exchange&nbsp;Commission (&ldquo;SEC&rdquo;). A preliminary prospectus supplement and accompanying base
prospectus relating to the offering will be filed with the SEC and will be available free of charge on the SEC&rsquo;s website
at&nbsp;http://www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">This
press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein,
nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. Copies of the preliminary
prospectus supplement and accompanying base prospectus relating to the offering may be obtained from Oppenheimer &amp; Co. Inc.,
Attention:&nbsp;Syndicate Prospectus Department,&nbsp;85 Broad Street, 26<SUP>th</SUP>&nbsp;Floor,&nbsp;New York, New York&nbsp;10004,
by telephone at 212-667-8563, or by e-mail at&nbsp;EquityProspectus@opco.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Actinium Pharmaceuticals, Inc. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actinium
Pharmaceuticals, Inc. is a biopharmaceutical company developing innovative targeted therapies for patients with cancers lacking
effective treatment options. Actinium&rsquo;s proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly
to cells of interest in order to kill those cells safely and effectively. The Company&rsquo;s lead product candidate Iomab-B is designed
to be used, upon approval, in preparing patients for a hematopoietic stem cell transplant, commonly referred to as bone marrow
transplant. A bone marrow transplant is often the only potential cure for patients with blood-borne cancers but the current standard
preparation for a transplant requires chemotherapy and/or total body irradiation that result in significant toxicities. Actinium
believes Iomab-B will enable a faster and less toxic preparation of patients seeking a bone marrow transplant, leading to increased
transplant success and survival rates. The Company is currently conducting a single pivotal 150-patient, multicenter Phase 3 clinical
study of Iomab-B in patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The Company&rsquo;s second product
candidate, Actimab-A, is currently in a multicenter open-label, 53-patient Phase 2 trial for patients newly diagnosed with AML
age 60 and over. Actimab-A is being developed to induce remissions in elderly patients with AML who lack effective treatment options
and often cannot tolerate the toxicities of standard frontline therapies. Actinium is also utilizing its alpha-particle immunotherapy
(APIT) technology platform to generate new drug candidates based on antibodies linked to the element Actinium-225 that are directed
at various cancers that are blood-borne or form solid tumors. Actinium Pharmaceuticals is based in New York, NY. To learn more
about Actinium Pharmaceuticals, please visit www.actiniumpharma.com and to follow @ActiniumPharma on Twitter please visit, www.twitter.com/actiniumpharma.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements for Actinium Pharmaceuticals, Inc. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
news release contains &ldquo;forward-looking statements&rdquo; as defined in the Private Securities Litigation Reform Act of 1995,
including statements regarding the proposed offering. These statements are based on management&rsquo;s current expectations and involve
risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking
statements may include statements regarding product development, product potential, or financial performance. No forward-looking
statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes
no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contacts:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actinium
Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve
O&rsquo;Loughlin<BR>
Principal Financial Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">soloughlin@actiniumpharma.com</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">Liolios
Investor Relations</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">Marek
Ciszewski, J.D.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">949.574.3860</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">ATNM@liolios.com</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>6
<FILENAME>f8k072817ex99ii_actinium.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY ACTINIUM PHARMACEUTICALS, INC. DATED JULY 28, 2017.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="ex99ii_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: Red"></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">Actinium
Announces Pricing of Public Offering of Common Stock and Warrants to Purchase Common Stock</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>New
York, NY &ndash; July 28, 2017</B> &ndash; Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (&quot;Actinium&quot; or
&quot;the Company&quot;), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective
treatment options, announced today the pricing of an underwritten public offering of 21,500,000 shares of its common stock
and warrants to purchase an aggregate of 18,275,000 shares of the Company&rsquo;s common stock at an offering price to the
public of $0.75 per share and related warrant. The warrants have an exercise price of $1.05 per share and have a term of
exercise of five years. The offering is expected to close on or about August 2, 2017, subject to customary closing
conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Oppenheimer
&amp; Co. Inc. is acting as sole book-running manager for the offering. Maxim Group LLC and Jones Trading Institutional Services
LLC are acting as co-managers for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
gross proceeds to Actinium from this offering are expected to be approximately $16.125 million, before deducting underwriting discounts
and commissions and other estimated offering expenses payable by Actinium. The Company intends to use the net proceeds from the
offering to fund clinical development of Iomab-B, Actimab-A, Actimab-M, its alpha particle technology platform, and for general
corporate purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
offering is being conducted pursuant to a shelf registration statement that was previously filed with, and declared effective
by the U.S. Securities and Exchange&nbsp;Commission (&quot;SEC&quot;). A preliminary prospectus supplement and accompanying base
prospectus relating to the offering has been filed with the SEC and a final prospectus supplement relating to the offering will
be filed with the SEC and will be available free of charge on the SEC&rsquo;s website at </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="background-color: white">http://www.sec.gov</FONT><FONT STYLE="background-color: white">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">This
press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein,
nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. Copies of the final prospectus
supplement and accompanying base prospectus relating to the offering may be obtained from Oppenheimer &amp; Co. Inc., Attention:&nbsp;Syndicate
Prospectus Department,&nbsp;85 Broad Street, 26<SUP>th</SUP>&nbsp;Floor,&nbsp;New York, New York&nbsp;10004, by telephone at 212-667-8563,
or by e-mail at&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="background-color: white">EquityProspectus@opco.com</FONT><FONT STYLE="background-color: white">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 4.5pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 4.5pt 0 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 4.5pt 0 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 4.5pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Actinium Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 4.5pt 0 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 4.5pt 0 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actinium
Pharmaceuticals, Inc. is a biopharmaceutical company developing innovative targeted therapies for patients with cancers lacking
effective treatment options. Actinium's proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly
to cells of interest in order to kill those cells safely and effectively. The Company's lead product candidate Iomab-B is designed
to be used, upon approval, in preparing patients for a hematopoietic stem cell transplant, commonly referred to as bone marrow
transplant. A bone marrow transplant is often the only potential cure for patients with blood-borne cancers but the current standard
preparation for a transplant requires chemotherapy and/or total body irradiation that result in significant toxicities. Actinium
believes Iomab-B will enable a faster and less toxic preparation of patients seeking a bone marrow transplant, leading to increased
transplant success and survival rates. The Company is currently conducting a single pivotal 150-patient, multicenter Phase 3 clinical
study of Iomab-B in patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The Company's second product
candidate, Actimab-A, is currently in a multicenter open-label, 53-patient Phase 2 trial for patients newly diagnosed with AML
age 60 and over. Actimab-A is being developed to induce remissions in elderly patients with AML who lack effective treatment options
and often cannot tolerate the toxicities of standard frontline therapies. Actinium is also utilizing its alpha-particle immunotherapy
(APIT) technology platform to generate new drug candidates based on antibodies linked to the element Actinium-225 that are directed
at various cancers that are blood-borne or form solid tumors. Actinium Pharmaceuticals is based in New York, NY. To learn more
about Actinium Pharmaceuticals, please visit www.actiniumpharma.com and to follow
@ActiniumPharma on Twitter please visit, www.twitter.com/actiniumpharma.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements for Actinium Pharmaceuticals, Inc. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
news release contains &quot;forward-looking statements&quot; as defined in the Private Securities Litigation Reform Act of 1995,
including statements regarding the closing of the offering and the anticipated use of proceeds. These statements are based on
management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from
those set forth in the statements. The forward-looking statements may include statements regarding product development, product
potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from
those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as
a result of new information, future events, or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 4.5pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Actinium
Pharmaceuticals, Inc. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve
O'Loughlin<BR>
Principal Financial Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">soloughlin@actiniumpharma.com</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">Liolios
Investor Relations</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">Marek
Ciszewski, J.D.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">949.574.3860</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">ATNM@liolios.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"></FONT></P>



<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex99i_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99i_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" ": F<# 2(  A$! Q$!_\0
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MIOF4A6Y##@9Y&>OK[@=<?QN?\'%/Q)^(^M:U^RU<176H/X#TG5/B(]RD;O\
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MU5\3KC4[^XGU77==NG>&)I'%CI5AY@&]^&2UL;2-P./F?(B57E=5/ZU?L^_
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MC)4(X6M7H0E&5:E3Q$ZE--.4$KV\REG635\VQ>0T,WRNMGF7X7#X['Y+2S#
MU,VP6"QC<<)C,7EM/%SQ^'PF*G"I"AB:^#I4:LXN-.I)V<]ZBBBN0],****
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MUW%=1&*[M+ZVF FM;ZTGAN;=B3'*H+*WYT_\&\_B;QI\9/A#\5O!?BF>ZO\
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M^-O#>D^(K)@P=K==1M(YIK.4C.VZL+CSK*Z3AH[B"1& 9>?0P1Z@_B*_%/\
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MBCA=9C2S&&0YAFE2GC*^+5*CF&)XGJ5L!##2P=:EE/#]!1HXZMB*LL777%?
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M#MI7\Q;*UU22SWW>G6I98K3[5&EW' BQS7$Y42G]ZV_X*'Z& <7&L>@QHDW
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M+8'U8',I'\&%).ZNN\)?L3^ OB)J=OXC\0:5$&219 K0QNA;@Y"R*VWC&XJ
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M:5VIG*,(3J3:C"$)SG)IM1A",ISDTHRDU&,)2:49-\ND9.T97\ ]1FC ]/\
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M,'0I2Q>&YI8V.#G)5H.G1J*5U[712+G R<GU_P#U<?EQZ4M>3^/H?3!1110
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MG-VMJK7[(\FU7]I?XRE3G4M/Y _YA)#'KP ;D_\ ZO;%>6:[^TK\8\/G4=/
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M%'A31RO%>'M;A_B;"9CP[XDX"6-R7..(:=#AK^RGAL7+"YE3X@C4QF,P6$6
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M@\?/XDTK1=7LM3NM"AOW\-)IXU:.REG&GSWDMG>"*"Y:.9EMIG:)44,?T?\
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MSPUY7E]/+V?V?MV8XVXVXXQ@8KXOPPXWX:X%Q7&E;,\#Q!F-/B7A7.^$,$L
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M?FN5?12S[,_";Q>\*>.N(N&5A?$GCW.?$K*\]X3P_$7UOA_B7-<ZAG>'P]?
M9ZJ.'Q^6977H4Z,'2Q-#%X[#XG%PKK#3AAZJ_/G]E7_@H7\!?BO\+?#LWCOX
MD>$OAQ\1M"T+3M-\8:!XTUNQ\.13ZAI]O%:SZYH%_J<MK8:MI>L-&+ZW2SGD
MO+(RO97EM&\(>3WCX+_M1>$?C]XK^)&G_#+1-;\0_#GX=VNGP?\ "X($">$/
M&'BJ<W4FJ^&/!\4\4-[K#Z':PP27FKV^ZPEFNDMXSM,$]S0U3]@O]CK6==;Q
M'J'[/7PYDU-[@74@ATJ6RTR2X#%S))H=E<V^B2%F9F=7T\I(23(K9KZ>\/\
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M*PT.+:>/CF-;%5)5*F&G+ /&N. IX>*CB8P4L;*D[0/G/%3P7\2_$KPL\/\
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M;!(W09_U:RRF6:.(C*F-)50H=I&T!:^K=6_9T2VC6+3@5CC54C4# "JH "@
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MYYC?W;?L<_M;>%?VDO EG=PW,5GXLTZ"&VUW1Y'7S8;H1@-/;H"2]K.V6B<
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M5H5Z]:O.O4E3BXTH<R48TZ:D^;EC%:MZMML6BBBOSX^@"BBB@ HHHH ****
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M:U5NI5JRC*I5J-SJ5)S;DRBBBI-0HHHH **** "BBB@ HHHH **** "BBB@
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MO%7[+WQ2.K:?K*:;JGAK5IM.URP$TKZ?>QVDXCO+:8(-LEO(JG:Q&Y,[LA@
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MPKI8:571HHHK^>3^U@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
7!1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex99ii_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99ii_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "4 F@# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M )$*OE_]BWX)3^=_PF/C'[-_:'V/_E[O/^)98:7SC1/[;\0>G]A_YZU_0'\
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M8SD$B '_ #@#^OU]*^(/<-"BBB@ HHHH ***K2_ZZ'ZG^8H LT55\[S?]1/
M<>^3V]S_ "]JGC^XOTH ?1110 456EE 'Z\_Y_(?B:(^@_X^.I^]T_\ U?UH
M LT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"^N:,->T'6M;]/$7)\+^-P  #H&<\Y/](_@KP+I_ANSA(A G&>1VQ^>,=?\
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M_!['^7Y#_P $T_VMO#?BW4/"OB/X9?\ $PM;S^Q?^$AM-8_XIF_TO/\ 8/\
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M_$_$^;\79O+-\WDG-II).^^[?ROV/Z%RW+<)E.$^I8+2*OUW_K^EM;&8"/\
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MP_G^P_\ R@8K_2"_;/\ V)/A7^U_X#G\)_$'PKX;\1VPNA>QVOB*UWZ=::F
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MX-EP=.EPM3=)<7<+)5I<5.=2E2C[&DN%J/LJM2JXU84I2E#\MO\ @H4BS_\
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M<(UJ=6EBHSC+_6F5:DY.-"5.K1=&4YSG3J5N64HTJ=*>)2IP\3PSR;COP_\
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MOA?2?#OA[P(GA[P/>>$-4T;3=$MW@5-8-SXBO!JJND>DA3"+;#QSF12SMO\
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M5A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX_2K59US=06=M->WTL-M;VUNUU<W%P5"V@"Y9B3@!%"MWSD8&<@4 6\#T_\
M'U_PHP/3_P ?7_"O*D^+OPTD;</B#X ;<I%OM\6Z$2<ON'/VH<8DTWA<X+ \
MYC\Q?^%R?#-T4K\0OA_^_'^CE?&VA?O..JG[1G@\_*&]*KZAB?\ H6O_ , E
M_P#*SS/[7RSIFD/OC_F>J;&]/U'^-1>6G]T5F6FI6.J6EM?Z7J5O<V-T/]%N
MK1AJ%A>*V?NM&3C)!Y60 X)W$YJ+5M9LM(TZYU34M4T[3M*M5^TW=_JEV-/T
MZ*Q*D[VU5\1ICAPS-\V=OW2"9/059+:37HU_F;0B$?3OWSW_ ,BF^6/?]/\
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MJ.A/&C:1K4>O,7T+7XS(#)X7\4HQ4:\?EW% _JL__!"WX17BB'_A9_BO%L<
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M?2H-\8,OFQQ1QRC!$J1PO+GO^[S)(H(Y( W'WZ?DA8>%OVF/BO\ LR:E\?\
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M5X:T/3)?'7Q&U/[=+H6A"+6?$?AJ]\/>&+5O)U77KCPV@'BR-I_#-Q,L222
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MOBWH_BWQQXCUR^U+4O&'C+Q'XHUKQA=ZO>:SJ6I_\)1KNM8UW\_;C'A_BO\
M5YU/3X=3TR[TR=R(;NU:T8=U!4KD],G&,CKU&#BOY0_VU/\ @AIX,\:?''Q!
M\7?!ECJ?AR;QGJZZYXOTKP^-(7PSK^INH?7-;7<!_8'B(@@Y' (*\.&\9C]J
M\&^-<'P[C98/'6]YW7_@.WJW=Z6]&?G_ !KDGUQ+&[V5G_5NWJ?*_P#P;J?'
M#Q_I_P >/VE]#UR^U*X^''B?PAX#\4:O:_+_ &;8_$_^V_[!.L'(;_BH'\.
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M@<[>$'&  3CDU^AW[ 4MZO['WP*BN)OM,G_"):HNX@A9(%U75)+9WX^5O+,
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M?!*]#?\ !8#Q[#$[,UQ\3/C):GS[G(W'P3K $B=26W1_*J@X [G%?H%^SO\
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MO::['=1I*Q92N_CY@\(_\$O6\+:5'X7UC]J/X_:[\-;17,_PTT7Q"/"F@:@
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MBU\5<+?ZXQJ5*$^+:?LG[)KA10J.&EHIP;48PFXR;D?G9_P68NT_X6W\%89
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MHUIJ>M_\)K)X2U6RTA]<TG4=%\0 L[:!XDT4W$)AEV-!=DQ/&DAD"_6/@_\
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M>$@IM4$DKR>/0'M@C%?SZ?\ !5;]G?X?>"[R'XW>%-9N-,\>_%;Q5I6A:O\
M#]2=2C\8:BVB21G5=$7S"^@7-J5T:.5\B.4D%,,Q6/\ :KX$Z!?>%?@=\+/"
MOBN:5]=\+?#7P/X?UJ20AW34-,T*T@F3@D%O,B+,<_*0%P&4U^;\:\'\$97P
M#X=\8\,9EQ.JN>4*]+BB'$D5&4,1PS3H0Q-6A*48-4EB:TH3FG4C."ISE5]M
M[6F?MOAEXC^(V:>+_BYX9\=93PO++."H\+<5\)\3<+WC3?"W%<\1'#X?B=2J
M5&^*I4:2K27)3:7/\=)TJC]6>VDGC!B,D9:33Y#N'*B&-U('?'.1^ YQ7\X_
M_!8NZM(_VA/AOYD1:(_"2T$<6XQM'(WC;7F,AP<G<Q9SGD!N^,U_1UK&ERZC
MIFHZ?:ZE>Z9/J%G=V<.HVH5;S3[MDD2/4H6QY>Z%@)%!55;*J"F\,OY@>,O^
M"6/@'XA^(%\6^//CY\>O'GB!;;^SQJWB;5?!VJWT>ECYO[)W'PM&JQ#J7"X)
MS@GK7=X&<7<+>'_'^%XSXCS*HL-A(XC]S0HU)U:DJ]&%.DHU*<X0IQHJ#;<W
MSRNE!6E-GC?2V\.^./%#PAS;@/@+)J>>YSG=?A>MS3XJI\+1A'AK$>UGSJK%
MJIS/EM3;4&^24FW3@S[-_9:MTD_9G^! :/)F^#_P^$A!Y54\(Z.%<$ @D##;
M",_-V)!'XJ?MB)#;_P#!4WX13JT/F2^(/V<[H!A]\#6Y$N-[?PDE0W;J1U)Q
M^NGP._9GNO@99WFE:+\<_C)XR\.-X<CT'0=$\=:UH6J:=X82$!=-U'1I4T&W
M<SQ!1'M<R(=JAD(4QU\R^(_^"6/@SQCXQ@^(GBSX_P#Q[\0^-XKC2KQ?$^HZ
MUX1?7E.@_P#(''FQ^%H]J18).V#G'S!2<#U_#;C#@CA+CGC/-L?Q7-9+Q!PE
MQ?AJ-6EPEQ15J5*G&%.K[TJ+JPE2^J2E"-6$IRE:TX4E!MGS'C7P#XG\?^$W
MAWPEDW!Z>?\ #7%W!W%55UN+^$X0C_J8^:-I\O+-\56E*G*"DJ=VZK>D#[(_
M:Q6$?LT_'A ^Q8OA!X\15 &%C7P]</DC'R$,=@&?F#''.<_G'_P1H2V@^%_Q
MI,<JS6\GCCPR8Y'0?*9?#)=@20<*DKQJ2/NC )!Q7W)\3OV9-1^+'PW\*_"_
M4_V@_C;I5AH^CZEIWBV^TK4_",6M_$W2=5M%BF7QPQ\,21Y^5FC'AQ=,8"5P
MS%2"O#_LX_L(>&?V9]=?6O _QA^,<^BW4SW^M>#=6O\ PG;^"];O#I"Z+YFI
M:9#X;60,4C24/!/'(DT<;*<QJ:\G(>).%<L\'_$3@S^U)RSSB+BKA6M24.%Z
MKI5:/"LI.#GBIV<)5.>/U91A4A",Y+VEJ9]#Q=P;XBYW](SPC\2L%PBH\'<$
M<(<5\*<5UI<6<*JJI<7*/.J=&*O./#$X-U5>$JK2]BMW/\=/V2?&1_9^_;^\
M5:?\5]0@T)+_ ,2?%+X?>(M2U5E5;+6/$&L)<>'=2DE8%46X9='0.PV@:^QS
MP*_IAO\ 4;&PLKC5;R\L]/T8VC7EWK%[)%:06$ 3>9&ED 4LBAW8%E;&<Y;D
M?(G[37[!GP1_:CNK?Q+X@CUKPMXZM[$6,7B[PQ=(E[=V$8 CMM=TR^BDM=7@
M@3<L2SPO.F\8=P0B^$>%?^"8NDV.GV'AGXD?M(?';XE?#?2A9);?"V]\3MX?
M\"ZAIT&Y1HNMZ/$DC7&C#"@VD9C8JC(I4I\WN>(G$WAGXL?ZO<59CGE?AO/,
M)PKAN%^+N$WPK6XBPU5\+4U2A+A=TJL*5:,W.7^RXI4Z$*TZ?M(M1BY?+>%?
M!7C3X$?ZV\!9)P?PEX@<%\0\7<6\6<)<7/BN'"TN%'Q34E4<.+J-2BY^SY8T
MN1\(J4XJ,XPBO:1</N#4OVB/A'I_P;G^/S^*K&X^%%MI+:W;>([.VOIX[^'>
MVDQMI:LL;ZUYLOF0QB&.3)1F!P@=,']GC]ICX3_M,^&]=\0?"[4'N8M$NEL-
M?TC6=)ETK4-'U$KYH2Z64X97CY5@QW@[@ K 5N?&#]GSX=?%?X*ZA\!=1M4\
M.^#+W2-.TO2;?0@MB^AIHSJVARZ0L8V1R:'+##)!&(_+&U5P Q0>9_LF?L:^
M"_V3]!\56.B^)-:\8:QXTO-.O-;\0ZW;:;IS/8Z,OEZ-I,>GVV1!'#'+*&E&
M9'+%5$#*#)^;X:CX<O@W.L9.7%<>-GQ9_P 8O0J\D\+'A-RBY+$2A"$9U+6Y
M_?ALE"')J?O6)Q/C.O$?A+ QRKA"?AB^$7+C#BASG'BG_6UQG'DX7H\TG[*4
MHIQ<H-<CJ-RYU&F?<%%%%?%'ZV%%%% !1110 54NK."\A-O<1AH>.,@8P/3'
M^>M6Z* /F7XC?!NRUF*>XL1C*\GL#W' SP<]?\"?XN?^#@/Q'\1OAM\>/V9_
M"MO_ &E;>![7P?X[\3V=I=_\2W3+_P =C6CH.N?A_P (X=$(&?\ F/\ ;O\
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MZDDG)-?SF?'C]E#0_&V@Z?XQ\*_V;<W'_$K_ .$;\0]_^P+KG;T]O;I7S_\
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MV<G>\GHV[+2-DK%BBBBN,]T**** "BBB@ HHHH **** "BBB@ HHHH ****
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M$=^M?EG\>/@C?_#Z]O\ 6=!TW^T?AMJLA2[L],&P^!'!*@*&QN\.L"-NW/\
MPAF1T\"Y'@S]:\+LZRC"YK'*,Y7NS2<6]K2;2UO:[<9)=W%KH?RW])#)N(L)
MPYF?&?#$HWR6$JO%<;WE4I1LW.,=VHJ2YK7M=/5:K\7OV+OVN/%/[.'CP:5J
M N&\'W%Z+/5_#Q&?[/8<@C/0CL>N?3-?UI>#?&&A>-?#>B>*M#U*PU#1]<LK
M*\LKJTN%NTE$@$F(I$&TX#!3)PP8.6&1S_'9\*?V-/B]^VE^U#\5O#?@J?4?
M"'PL\-_$G4S\0_C#>6?_ !+_  N3JS2?V%X#5A_PC?B+XBF/#J$&?!BAW<%5
M7_A+_P"M/X#_  .^'W[.?PU\-_"?X8:3/I_A3PLK):)?ZMJ>K:OJM_,575]9
MUG6]5:2;6M9NVB,LLLTC,S1'(CC5%A^K\?*' 6'QN3?V&Y/C9P<N,6K.%VHN
M#O=^][RDDE>S<I6]V_Q7T/,Q\5,TRC.,9Q*X_P#$+VH_ZG)J2LUO'A!)+_C#
MU"Z@Y[-^XK<U_?Z***_GH_MD**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ex5i.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5i.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !P K@# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZE'GQIJ,3>(?&-T\GFRWFLW>)+DN_P#&8_DA#=UA4^]?C7_P>"?\I6/V?O\
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M^"D_[!DT7@SXT^%]1^*_P[O4UWPFD-O=QSW9)5+JT5S" /,B^<<C,D$/('-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFGRZGXLNM(N;?1X(YHH?]+>)DB<O*RH%5RK$D]%.,GB@#GO$O[3_ ,(_AKX
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MK#L:Y6P\??"2?6].T^T3PU+)=ZK)I%E-;Z6'M)+^,.7MTN%C\GSE^SR H'W
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M\N#<VRI:V,$D4\F?+DG55Y+L ?8^O>$]*\5+&-3TW3]1$.?+%U;I-Y>[@XW
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MK$NM7MQJ=RMS=RR.JHD?F!%_=1HH5%(X^8DEF8D ^@Z_G!_X/![Z&+_@JQ\
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M,7CZ+4H8($B\<>*I=<6P6+=@P&1049MV&))+;5STH ]EHHHH **** "BBB@
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M0%58 D3_ +$G[7=C^VQ\$[7QUIGA_P 2:!I6JRRS::-7TV6S:]LFED%K<H7
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M_P#R37L%% 'C_P#POGXD_P#1#/$W_A1Z/_\ )-'_  OGXD_]$,\3?^%'H_\
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M_P#POGXD_P#1#/$W_A1Z/_\ )-'_  OGXD_]$,\3?^%'H_\ \DU[!10!X_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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46\*< <(@ ' ';M6C0 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
